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ABSTRACT 
Neutrophils are one of the essential components of the innate immune system that play a 
critical role in the host's defense against bacterial and fungal infections. Hematopoietic 
growth factors are a class of regulatory cytokines that are required for stimulation, 
proliferation, and differentiation of blood cells. Granulocyte-colony stimulating factor 
(G-CSF) is a member of this regulatory family of cytokines that almost exclusively 
stimulates proliferation and differentiation of precursor neutrophilic cells in the bone marrow 
and modulates functional activities of mature neutrophils in the circulation. Treatment with 
G-CSF enhances phagocytic, bactericidal, and fungicidal activities of neutrophils. A cDNA 
clone encoding bovine G-CSF (bG-CSF) was isolated and sequenced from an endothelial 
cell cDNA library. The full-length cDNA was 1460 nucleotides with 585 nucleotides 
comprising the open reading frame. The deduced G-CSF protein consisted of 174 amino 
acids with a 21 amino acid-long signal peptide. This cDNA was expressed in Escherichia 
coll and the biological activities of the solubilized protein from purified inclusion bodies 
were examined. Flow cytometric analysis of membrane antigen density of neutrophils 
activated with this oxidized and refolded protein revealed an upregulation of CDl la, CDl lb, 
CDl Ic, and CD 18. Expression of CD62L was decreased while expression of CD 14 
remained unchanged. These findings indicate that recombinant bG-CSF expressed in E. coli 
is biologically active and exerts the same type of effects on neutrophils in vitro as those of 
human G-CSF (hG-CSF). Bovine G-CSF cDNA was also subcloned into a mammalian 
expression vector and tested for its in vivo efficacy as an immunomodulator in calves. 
Results obtained firom the preliminary studies were inconclusive. Using the same endothelial 
cell cDNA library mentioned above, we also cloned and sequenced a full-length cDNA 
encoding bovine interleukin-7 and a partial cDNA sequence encoding bG-CSF receptor. 
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GENERAL INTRODUCTION 
Dissertation Organization 
The following dissertation is organized into a general introduction, two journal papers, and a 
general conclusion. The general introduction is a review of the literature that focuses on the 
gene structure and biology of granulocyte-colony stimulating factor and its cUnical applications 
for the prevention and treatment of infectious diseases. The first paper is cloning, sequencing, 
and analysis of cDNA encoding bovine G-CSF (bG-CSF). The second paper describes the 
expression, purification, and solubilization of bG-CSF protein and characterization of its 
biological activities in vitro. The first paper has been published in Veterinary Immunology and 
Immunopathology. The second paper will be submitted to the same journal for publication. 
General conclusions follow the second paper. 
Literature Review 
Introductions 
Innate immunity is an evolutionary and ancient defense mechanism that serves as the first 
line of defense against microbial infections (Fearon and Locksley, 1996). Polymorphonuclear 
leukocytes (neutrophils, PMNs) are the first line of professional phagocytic cells of the innate 
immune system that migrate into tissues in response to inflammatory stimuli. Their major 
effector function is phagocytosis and killing of microorganisms by generation of reactive 
oxygen radicals and release of lytic enzymes stored in granules (Gabay, 1988, Buchta, 1990, 
Brown, 1995). The central importance of neutrophils in host defense is more apparent in 
neutropenia and deficiencies in neutrophil functions where humans and animals are predisposed 
to life threatening fungal and bacterial infections (Renshaw and Davis, 1979, Anderson and 
Springer, 1987, Amaout, 1990, Amaout, et al., 1990, Kehrli, et al., 1990, Etzioni, et al., 1992). 
It has also been shown that numerous factors such as stress and hormonal changes associated 
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with parturition, drugs, glucocorticoids, bacterial and viral infections and nutritional deprivation 
have detrimental effects on migration and functional activities of neutrophils. These adverse 
effects render animals susceptible to infectious diseases with serious clinical complications 
(Lopez, et al., 1986, Nagahata, et al., 1988, Kehrli, et al., 1989b, Kehrli, et al., 1989a, Saad, et al., 
1989, Anderson, et al., 1991, Cai, et al., 1994, Stevens and Czuprynski, 1996). 
It has been shown that many cytokines including hematopoietic growth factors can enhance 
functional activities of neutrophils (Steinbeck and Roth, 1989). Interferons, interleukin 1, 
interleukin 2, tumor necrosis factors, and colony-stimulating factors are produced by different 
cells of the immune system in response to bacterial and viral infections. These cytokines can 
bind to their receptors on neutrophils and modulate some or all of the following neutrophil 
functions: adherence, cell surface receptor expression, migration, release of lytic enzymes, 
respiratory burst, and microbicidal activities (Ming, et al., 1987, Seow, et al., 1987, Shalaby, et 
al., 1987, Ferrante, et al., 1988a, Ferrante, et al., 1988b, Nathan, 1989, Yuo, et al., 1989, Wewers, 
et al., 1990, Roilides, et al., 1991, Ferrante, et al., 1993, Hansen, et al., 1993). Clinical 
applications of recombinant cytokines, hematopoietic growth factors in particular, have proven 
the crucial importance of these regulatory molecules in combating neutropenia, suppression of 
neutrophil functions, and infectious diseases. Understanding the molecular biology and 
functional activities of these cytokines is essential for their use and applications in clinical 
settings. 
Hematopoietic growth factors 
Hematopoietic growth factors are a group of glycoproteins that regulate survival, clonal 
proliferation and differentiation of bone marrow progenitor cells (Burgess and Metcalf, 1980, 
Metcalf, 1985). At least five hematopoietic growth factors have been identified and their genes 
have been cloned in different species: Granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (Gough, et al., 1984, Wong, et al., 1985, Leong, et al., 1989), macrophage colony-
3 
stimulating factor (M-CSF) (Kawasaki, et al., 1985, Wong, et al., 1987, Ladner, et al., 1988), 
G-CSF (Nagata, et al., 1986a, Tsuchiya, et al., 1986, Han, et al., 1996, Kulmburg, et al., 1997, 
Heidari and Kehrli, 2000), interIeukin-3 (IL-3) (Yang, et al., 1986), and erythropoietin (EPO) 
(Jacobs, et al., 1985). These various factors interact with separate receptors but sometimes 
overlapping progenitor cells. GM-CSF stimulates the proliferation and differentiation of 
colonies of neutrophils, monocyte/macrophages, and eosinophils (Platzer, et al., 1985, Metcalf, 
1986). M-CSF is required for growth, survival and differentiation of mononuclear phagocytic 
cells (Ulich, et al., 1990). IL-3 or multi-colony stimulating factor is shown to not only stimulate 
granulocyte and macrophage colony formation, but also to have the ability to stimulate the 
growth and differentiation of multi-potential cells, eosinophils, megakaryocyte progenitors, and 
mast cells (Lopez, et al., 1987, Messner, et al., 1987, Emerson, et al., 1988). EPO is a semm 
glycoprotein that is specifically required for the growth, proliferation, and maturation of 
committed erythroid progenitor cells in the bone marrow into circulating red blood cells 
(Krantz, 1991). Among the colony stimulating factors, G-CSF stimulates almost exclusively 
the proliferation and maturation of precursor neutrophilic granulocytes in the bone marrow and 
modulates functional activities of mature neutrophils in the circulation (Nagata, et al., 1986a, 
Nomura, et al., 1986, Tamura, et al., 1987). The remainder of this introduction will focus on the 
gene structure, biology, and clinical applications of G-CSF. 
Granulocyte-colony stimulating factor 
Since the original functional description of human G-CSF in 1979 (Nicola, et al., 1979), this 
hematopoietic growth factor has been purified from culture media, expressed in E. coli, yeast 
and Chinese Hamster Ovary (CHO) cells, and evaluated extensively in preclinical and clinical 
trials. Recombinant human G-CSF (rhG-CSF) has been licensed and routinely used for 
prevention and/or treatment of neutropenia, infectious diseases, and neutrophilic disorders. 
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Cellular sources of G-CSF 
Primary monocytes or macrophages, fibroblast and related mesenchymal cells, endothelial 
cells, and bone marrow stromal cells are all cellular sources of G-CSF (Rambaldi, et al., 1987, 
Fibbe, et al., 1988, Vellenga, et al., 1988, Zsebo, et al., 1988, Tweardy, et al., 1990, Kittler, et al., 
1992, Zoellner, et al., 1992). It has also been shown that conditioned media from almost all 
murine tissue cultures, specifically when stimulated with endotoxin, contain substantial levels of 
G-CSF (Nicola and Metcalf, 1982). GM-CSF stimulated human PMN cells also express 
G-CSF mRNA (Lindemann, et al., 1989). 
G-CSF gene structure 
Human and murine genes for G-CSF have been cloned, sequenced, and mapped to 
chromosome 17 and 11, respectively (Nagata, et al., 1986b, Tsuchiya, et al., 1987). The gene 
localization for G-CSF is therefore different from GM-CSF, M-CSF, and IL-3 that are all 
mapped to chromosome 5 of humans. This observation in addition to the lack of strong 
sequence homology between G-CSF and the other colony stimulating factors encoded on 
chromosome 5, suggests that G-CSF might have evolved from a separate primordial gene in the 
evolution of mammalian development. 
There are five exons and four introns in both human and murine G-CSF genes, with a great 
deal of homology in the coding regions. Comparison of the G-CSF cDNA sequences reveals 
that G-CSF has been greatly conserved in the evolution of species. For example, bovine 
G-CSF cDNA has 95, 89, 85, and 76 % identity with ovine, porcine, human, and murine 
G-CSF cDNA, respectively (Heidari and Kehrli, 2000). This high degree of conservation 
agrees with the observation that G-CSF, unlike human GM-CSF, and IL-3, is not species 
restricted and can stimulate the generation of neutrophilic granulocytes from different 
mammalian species (Nagata et al., 1986a, Moore, 1988). One unusual feature of the G-CSF 
cDNA sequences lies in the 5' region, upstream from the mature protein. The signal peptide 
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sequence of human (Nagata et al., 1986a) and murine (Tsuchiya et al., 1986) G-CSF genes are 
30 amino acids in length, while this signal peptide is only 21 amino acids long in bovine 
(Heidari and Kehrli, 2000), rat (Han et al., 1996), and porcine (Kulmburg, et al., 1997) 
G-CSFs. Why evolutionarily distant species such as human and murine or bovine and rat have 
this odd similarity in their gene structures, and what the significance of this observation is in the 
regulation of their expression, is not clear. 
G-CSF protein structure 
Shortly after cloning, the human G-CSF gene was expressed in E. coli (Souza, et al., 1986) 
and subsequently in CHO cells (Kubota, et al., 1990, Monaco, et al., 1996). Native human 
G-CSF is a protein of 174 amino acids that contains no consensus sequence for 
N-glycosylations (Asn-X-Ser/Thr). It is however, minimally O-glycosylated at Thr-133 and 
has a molecular weight of 19,600 daltons (Welte, et al., 1985, Kubota et al., 1990). Bovine, 
porcine and ovine G-CSF cDNAs also encode for 174 amino acids and all have a conserved 
Thr residue at position 133 and are most likely to be O-glycosylated at this position like their 
human counterpart (Nagata et al., 1986a, O'Brien, et al., 1994, Kulmburg et al., 1997). Murine 
and rat G-CSF encode for proteins that contain 178 and 194 amino acids, respectively 
(Tsuchiya et al., 1986, Han et al., 1996). The E. coli expressed-nonglycosylated form of 
G-CSF protein has biological activities quite similar to native and recombinant glycosylated 
protein (Kubota, et al., 1990, Tanaka, et al., 1997). Glycosylation, however, appears to stabilize 
the protein and protect it from polymerization at neutral pH (Oh-eda, et al., 1990). The amino 
acid sequences of human, bovine, porcine, and ovine G-CSF protein contain five cysteine 
residues at position 17,36, 42,64, and 74. Cys-17 is a free residue and non-essential for 
activity, while Cys-36, Cys-42, Cys-64, and Cys-74 are critical for intramolecular disulfide 
bridge formation (Lu, et al., 1989). Figure 1 represents the amino acid sequences of human and 
bovine G-CSF. Residues above the primary sequence indicate the substitutions for bovine 
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OOH 
Figure 1. Amino acid sequences of human and bovine G-CSF. The primary sequence and the 
numbering system are for human G-CSF. Residues shown above the main sequence are 
substitutions in bovine G-CSF. A free thiol (Cys-17) and two disulfide bonds are assigned by 
solid bars. Insertions in the bovine sequence are shown in triangles, and deletions are 
underlined (Modified from: Garland, et al., 1997). 
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G-CSF. Disulfide bonds are shown in bold bars. 
The three-dimensional structures of recombinant human G-CSF have been determined by 
X-ray crystallography (Hill, et al., 1993). The structure of human G-CSF is an antiparallel 
4- a helical bundle with up-up-down-down connectivity and a left-handed twist (Figure 2). 
These four stretches of helices are localized between residues 11 and 41 (helix A), 71 and 95 
(helix B), 102 and 125 (helix C), and 145 and 170 (helix D). Helices A and B are aligned 
paralleled in an up-up orientation, and helices C and D are antiparallel to A and B in a down-
down alignment. In addition to these four major helices, a short helical section exists as part of 
the AB loop connecting A and B helices (Zink, et al., 1994). The ribbon plot of this structure is 
depicted in Figure 3. The 4-a helical bundle is a common feature among many cytokines, 
including growth hormone (Abdel-Meguid, et al., 1987), GM-CSF (Diederichs, et al., 1991), 
IL-2 (Mott, et al., 1992), IL-4 (Redfield, et al., 1991, Wlodaver, et al., 1992), IFN-y (Ealick, et al., 
1991), IFN-P (Senda, et al., 1992), and M-CSF (Pandit, et al., 1992). This structural similarity 
exists despite the lack of sequence homology among the members of this class. The 
conformational integrity of this three-dimensional structure is crucial for maintaining the 
biological activities of the protein. It has been shown that the maintenance of both 
intramolecular disulfide bridges is essential for proper folding and conservation of G-CSF 
activity (Lu, et al., 1992). 
Studies have shown that chemical modifications of rhG-CSF and site-directed mutagenesis 
of certain amino acid residues can increase the stability and enhance pharmacological activities 
of the protein. Instability of rhG-CSF stored in solution with pH >7 (Oh-eda et al., 1990) is 
attributed to the free cysteinyl residue at position 17 (Ishikawa, et al., 1992, Arakawa, et al., 
1993). Using a sulfhydryl reagent, it was shown that Cys-17 is a partially solvent-exposed 
residue, indicating that this exposure has a major role in the instability of the G-CSF protein 
(Arakawa, et al., 1993). Protonation of Cys-17 at acidic pHs, results in functionally stable 
protein, supporting the notion this residue plays a critical role in the overall stability of a 
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Figure 2. Connectivity diagram of rhG-CSF. The length of the secondary structural elements 
are drawn in proportion to the number of residues (From: Garland et al., 1997). 
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Figure 3. Ribbon diagram of recombinant G-CSF highlighting its structural elements. Two 
pairs of helices are connected by long crossover connections AB and CD. The fifth helix 
connecting A and B helices along with two disulfide bonds restrict the conformational freedom 
of AB loop (From: Lovejoy, et al., 1993). 
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biologically functional protein. This observation was further confirmed by generation of a 
Cys-17 —> Ser analog (ND 28) which is extremely stable at neutral pH and at higher 
temperatures (Okabe, et al., 1990, Ishikawa, et al., 1992, Arakawa et al., 1993). This tailored 
rhG-CSF was shown to maintain the native four a-helical bundle structures and to have more 
potent granulocytic activity than the wild type hC-CSF (Fujii, et al., 1997). 
Mutations generated by deletions or tandem repeats with the last 18 amino acid residues of 
COOH-terminus, resulted in loss of biological activities, presumably due to alteration of the 
tertiary structure of the protein. Mutants without N-terminal 4, 5,7, or 11 amino acid residues, 
however, maintained the biological activity (Kuga, et al., 1989). It has also been shown that point 
mutations at Leu-35 and Glu-46, as well as generation of neutralizing antibodies to the region of 
the protein comprising these residues (residues 20 — 46), cause substantial reduction in the 
activity of the protein. It is suggested that this region in addition to residues 165—174, is 
involved in the receptor binding site (Osslund and Boone, 1994). 
Glycosylated and E. coli derived rhG-CSF have a short half-life and are rapidly cleared from 
the circulation (Tanaka, et al., 1989). Covalent conjugation of polyethylene glycol (PEG) to 
rhG-CSF as well as its tailored mutant, ND28, has been shown to greatly improve their 
biological properties and specific activities. This chemical modification increased the stability 
of both molecules, decreased the rate of clearance in the plasma, and maintained the three 
dimensional conformation of the proteins (Satake-Ishikawa, et al., 1992, Yamasaki, et al., 1994). 
Larger PEG (higher molecular weight) was more effective in enhancing the pharmacological 
activities of the proteins. 
G-CSF receptor and signal transduction 
Granulocyte-colony stimulating factor interacts and exerts its effects through a specific 
transmembrane receptor on the target cells (Nicola and Metcalf, 1984). Using iodinated 
G-CSF, these receptors have been found on cells of neutrophilic lineage, myeloid leukemic 
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cells, placenta, platelets, trophoblastic cell lines, and human vascular endothelial cells (Nicola, et 
al., 1985, Park, et al., 1989, Uzumaki, et al., 1989, Demetri and Griffin, 1991, Shimoda, 
et al., 1993). Physiological significance of the expression of G-CSF receptor (G-CSFR) on 
non-hematopoietic cells is unclear. Genes for human and murine G-CSFR have been cloned 
and sequenced (Fukunaga, et al., 1990b, Nagata and Fukunaga, 1991). cDNA analysis reveals 
that human and murine G-CSFR encode for 813 and 812 amino acids, respectively (Fukunaga, 
et al., 1990a, Fukunaga et al., 1990b). There is more than 60% homology at the amino acid 
level between the two proteins, which is consistent with the observation that G-CSF from one 
species can bind and activate the PMN from another species. 
G-CSFR is a member of the hematopoietic receptor superfamily which is characterized by 
specific structural features (Bazan, 1990b, Bazan, 1990a). It consists of a cytokine receptor 
homology (CRH) domain (also called hemopoitein receptor domain) that is defined by the 
presence of four conserved Cys residues and a conserved WSXWS (Trp-Ser-X-Trp-Ser, where 
X can be any amino acid) motif, an immunoglobulin-like domain, three fibronectin type HI 
domains, a transmembrane domain devoid of apparent enzymatic activity, and a cytoplasmic 
domain (Bazan, 1990a, Bazan, 1990b, Fukunaga et al., 1990a, Fukunaga et al., i990b, Nagata 
and Fukunaga, 1991). Figure 4 is a schematic representation of G-CSFR, depicting important 
structural and functional domains. Other members of this family includes receptors for 
leukemia inhibitory factor, IL-3, EL-5, IL-6, GM-CSF, and growth hormone. Although the 
cytoplasmic domains of these receptors lack the consensus sequence for tyrosine kinases, they 
are absolutely essential for signal transduction induced by ligand binding (Fukunaga, et al., 
1991, Ziegler, et al., 1993). The binding of G-CSF forms a tetrameric structure with its receptor, 
consisting of two G-CSF and two G-CSFR molecules (Layton, et al., 1999). The structure of 
this complex is not determined and it is not clear whether G-CSF and G-CSFR have one or two 
binding sites. What is clear, however, is that this homo-oligomerization is essential for signal 
transduction (Horan, et al., 1996). As mentioned above, G-CSFR lacks intrinsic tyrosine kinase 
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Figure 4. Stylized representation of the G-CSF receptor The extracellular region of the 
molecule comprises an NHo-terminal immunoglobulin-like domain; a typical hematopoietin 
receptor family domain, containing the WSXWS motif; and three fibronectin type III domain 
repeats. In the intracytoplasmic domain, areas 1 and 2 are required for transduction of a 
maximum proliferative signal. Area 3 contains sequences necessary, but not sufficient, for the 
delivery of a differentitive signal (From: Garland, et al., 1997). 
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activity but is capable of activating cytoplasmic tyrosine kinases (Fukunaga et al., 1990a, 
Demetri and Griffin, 1991). Binding of G-CSF to its receptor induces phosphorylation of 
JakI, Jak2 (Janus tyrosine kinases), and STAT3 (a signal transducer and activator of 
transcription) (Shimoda, et al., 1994, Tian, et al., 1994). Activation of G-CSFR-cytoplasmic 
associated Jaks results in tyrosine phosphorylation of STAT proteins. Homo-and 
heterodimerization of these activated transcriptional factors lead to their translocation to the 
nuclei where they modulate the transcription of specific genes by binding to regulatory elements 
(Nicholson, et al., 1995, Tian, et al., 1996, Darnell, 1997). Deletion mutation studies have 
revealed that the extracellular domain of G-CSFR, specifically the highly conserved CRH 
region, is essential for ligand binding, while the cytoplasmic domain is critical for signal 
transduction (Fukunaga, et al., 1991). These investigators reported that the region comprising 
the membrane-proximal 100 amino acids of the cytoplasmic domain is required for proliferation 
(growth) signals, whereas both the membrane-proximal and COOH-terminus of the domain are 
needed for differentiation signals. 
Like the other members of the receptor family, a cDNA encoding a soluble, secreted form of 
G-CSFR has also been isolated that lacks most of the transmembrane sequence (Fukunaga, 
et al., 1990b). The physiological significance of this soluble receptor is not clear but it is 
speculated that it may function as a "sink" for removing excess G-CSF from the circulation 
and therefore controlling its biological activities (Rapoport, et al., 1992). 
Biology and clinical applications of G-CSF 
The stimulatory effect of G-CSF on the in vitro formation of neutrophil clusters and colonies 
from culture of human and murine bone marrow cells has long been recognized (Nicola et al., 
1979, Burgess and Metcalf, 1980, Metcalf and Nicola, 1983). G-CSF has also been shown to 
elevate the number of functionally normal neutrophils in preclinical murine, hamster, and non-
human primates (Zsebo, et al., 1986). Intravenous or subcutaneous injections of G-CSF in 
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healthy young or elderly human volunteers induce a temporary neutropenia followed by a dose 
dependent steady increase of neutrophils in the circulation ((Zsebo, et al., 1986, Morstyn, 
et al., 1988, Chatta, et al., 1994). The initial depression is thought to be due to margination of 
neutrophils to the endothelial cells. Leukocytosis induced by G-CSF plateaued a few days after 
daily injection of G-CSF and the peak levels were as high as tenfold of the normal PMN levels 
in the circulation of the subjects studied. The rapid increase of PMN counts after the initial 
depression is most likely due to the release of large storage pool of mature neutrophils in the 
bone marrow. Subsequent sustained increase, however, can be explained by G-CSF-induced 
production of fresh and functionally active neutrophils. 
Indirect evidence from two independent studies shows that the main physiological role of 
G-CSF is not only to act as a positive regulator of neutrophil numbers in baseline 
hematopoiesis, but also induce neutrophilia in stress and infections. In one study, dogs 
receiving repeated injection of hG-CSF developed neutralizing antibodies that cross-reacted 
with native canine G-CSF. This "immunization" induced chronic neutropenia lasted for up to 
four months (Hammond, et al., 1991). Severe neutropenia was also induced in dogs by 
injection of anti-G-CSF antibodies. These observations indicate that G-CSF is essential for 
maintenance of normal neutrophil counts. Evidence that precursor neutrophilic cells in the bone 
marrow of these animals had normal early stage formations, argues strongly that other 
cytokines might be involved in the initial phases of neutrophil development (Lieschke, et al., 
1994). In a second experiment, G-CSF knockout mice were shown to also have chronic 
neutropenia but normal, yet reduced, bone marrow formation of precursor neutrophilic cells 
(Lieschke, et al., 1994). These animals had positive response to iG-CSF administration by 
increasing their blood neutrophil numbers to normal counts. It was also shown that in 
comparison with normal mice, G-CSF-deficient mice had high mortality rates upon challenge 
with Listeria monocytogenes. Results from these experiments indicate that even though 
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G-CSF is an essential growth factor for maintenance of neutrophil production, it is not an 
absolute requirement for generation of mature neutrophils in the bone marrow. Redundancy 
and overlapping functions among hematopoietic growth factors could explain this observation 
(Metcalf, 1993). 
In addition to its role in controlling day-to-day regulations of neutrophil development, 
G-CSF is also essential for induction of the neutrophilia in response to stress and infections. 
Several studies have shown that the serum concentration of G-CSF is greatly increased in 
infection and neutropenia (Kitagawa, et al., 1987, Cheers, et al., 1988, Mempel, et al., 1991, 
Cebon and Layton, 1994, Cebon, et al., 1994). The increased level of G-CSF in severe 
infections is accompanied by increased neutrophil counts in the circulation. This observation 
suggests that G-CSF functions in a feedback mechanism in stress and emergency situations 
(Dale, et al., 1995). 
Studies in non-neutropenic animal model of infections have shown G-CSF plays a key role 
in mediating neutrophil responses to microbial infections. Mice pretreated with G-CSF had 
dramatic improvement in host defense against Pseudomonas aeruginosa challenge (Yasuda, 
et al., 1990). G-CSF improved survival rate of mice in a P. aeruginosa bum wound infection 
model, specifically when combined with antibiotic therapy (Mooney, et ai., 1988, Silver, et al., 
1989). G-CSF has also been found beneficial in a variety of peritonitis models where its 
administration prior to or shortly after the onset of disease greatly enhanced survival rate as well 
as modifying histopathology of afflicted organs (O'Reilly, et al., 1992, Goya, et al., 1993). 
G-CSF treatment of SCID and normal mice for five days after intravenous inoculation with 
Listeria monocytogenes improved survival rate and reduced bacterial counts in the liver 
(Serushago, et al., 1992). This augmentation of antibacterial activity is directly attributed to 
enhancement of the functional activities of activated neutrophils, but not to y/5 T cells or 
activated macrophages, as the SCID mice also benefited from this treatment (Kayashima, et al., 
1993). 
16 
In an experimentally induced intra-abdominal sepsis, pre- or immediate-post treatment of rats 
with G-CSF improved host defense by reducing bacterial and endotoxin levels and suppressing 
TNF and endothelin-1 concentrations (Lundblad, et al., 1996). G-CSF treatment of rats in this 
experiment did not induce neutrophil-mediated tissue damage. In another study, administration 
of G-CSF in addition to penicillin G, significantly improved the survival rate of immune 
competent rabbits with Gram-negative sepsis complicated with neutropenia (Smith, et al., 1995). 
G-CSF treatment of these rabbits for short therapeutic duration did not induce clinically evident 
toxicity, and G-CSF in combination with penicillin G was more effective than antibiotics alone. 
Kanazawa et al. have shown that treatment of guinea pigs with rG-CSF decreased endotoxin-
induced pulmonary edema and alveolar capillary protein leakage (Kanazawa, et al., 1992). In a 
similar experiment, mice pretreated with rhG-CSF were protected against LPS-induced lethality 
(Gorgen, et al., 1992). This protection was apparently mediated by suppression of circulating 
TNF. 
In experimentally induced colitis in rabbits, it was shown that high dose therapy with 
G-CSF resulted in a marked decrease of proinflammatory mediators, leukotriene and 
thromboxane B, (Hommes, et al., 1996). These authors conclude that G-CSF may have 
potential anti-inflammatory effects in the bowel mucosa. 
Prophylactic efficacy of rG-CSF has also been proven in experimentally induced mastitis in 
dairy cows. In a coliform mastitis model, G-CSF was shown to significantly improve clinical 
responses to E. coli challenge by reducing the number of new infections, enhancing the rates of 
bacterial clearance, and reducing clinical severity scores (Kehrli, et al., 1993). In some earlier 
studies with Staphylococcus aureus-xryduced mastitis in periparturient cows, administration of 
rG-CSF increased the number and functional activity of neutrophils, prevented some aspects of 
immunosuppression associated with periparturient period, and reduced the number of new 
infections. Shedding of S. aureus in lacteal secretion, however, was unaffected (Nickerson, 
et al., 1989, Kehrli, et al., 1991). 
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Observations from these and other animal infection models suggest that G-CSF may be more 
efficacious in prevention or treatment of diseases induced by Gram-negative organisms than 
Gram-positive ones. The underlying assumption in all of these experiments was that preventing 
or ameliorating bacterial infections was not only due to an increase in neutrophil numbers, but 
also augmentation of the biological activities of preexisting neutrophils by G-CSF treatments. 
Indeed many in vivo and in vitro studies have shown that G-CSF, in addition to playing an 
essential role in regulation of granulopoiesis, significandy modulates the functional activities of 
mature and developing neutrophils. G-CSF increases CDllb/CD18 (Mac I) expression on 
neutrophils (Kitagawa, et al., 1987, Yuo et al., 1989, Avalos, et al., 1990), and enhances 
L-selectin affinity binding before promoting its shedding (a prerequisite for P2-mediated tight 
adhesion ) (Spertini, et al., 1991, Yong and Linch, 1992, Ohsaka, et al., 1993, liles, et al., 1994, 
Turzanski, et al., 1997). In vivo administration of rG-CSF increases the expression of CD14 
(LPS receptor), as well as receptors for IgG (FcRl, CD64) (Hansen, et al., 1993, Ohsaka and 
Saionji, 1998). G-CSF also enhances chemotactic (Wang, et al., 1988), phagocytic (Ogle, et al., 
1990, Roilides et al., 1991), and bactericidal and fungicidal activities of neutrophils in vitro 
(Roilides et al., 1991, Roilides, et al., 1993). G-CSF has also been shown to prolong survival 
and delay apoptosis of neutrophils (Balazovich, et al., 1991). 
At the present time rhG-CSF is approved by the FDA as a therapeutic agent for prevention or 
reduction of febrile neutropenia and associated infections after myelosuppressive chemotherapy, 
and acceleration of recovery from autologous bone marrow transplantation (Gabrilove, 1992). 
The principal aim in these clinical settings is to reduce the risk of infection, minimize the need 
for hospitalization and intravenous antibiotics, and improve overall quality of patients' lives. 
Despite the extensive and prolonged use of G-CSF in clinical settings, there is very little 
evidence of toxicity or other side effects associated with administration of this hematopoietic 
growth factor. Mild to moderate bone pain and rare adverse reactions of slight increases in 
alkaline phosphatase, lactate dehydrogenase, and urate have been the most common 
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observations in patients using high doses of G-CSF for extended periods (Neidhart, et al., 1989, 
Crawford, et al., 1991, Woll, et al., 1995, Bociek and Armitage, 1996). In addition to normal 
hematopoietic cells, some human acute and chronic myeloid leukemia cells also express 
receptors for G-CSF (Souza, et al., 1986, Motoji, et al., 1991). The effect of G-CSF 
administration on the growth and proliferation of these non-hematological cancer cells is a 
concern and has not been well studied in clinical trials. 
References 
Abdel-Meguid, S.S., Shieh, H.S., Smith, W.W., Dayringer, H.E., Violand, B.N. and Bentle, 
L.A., 1987. Three-dimensional structure of a genetically engineered variant of porcine 
growth hormone. Proc Natl Acad Sci U S A, 84: 6434-7. 
Anderson, D.C. and Springer, T.A., 1987. Leukocyte adhesion deficiency: an inherited defect in 
the Mac-1, LFA-1, and pl50,95 glycoproteins. Annu Rev Med, 38: 175-94. 
Anderson, N.V., Youanes, YJD., Vestweber, J.G., King, C.A., Klemm, R.D. and Kennedy, G.A., 
1991. The effects of stressful exercise on leukocytes in cattle with experimental pneumonic 
pasteurellosis. Vet Res Commun, 15: 189-204. 
Arakawa, T., Prestrelski, S.J., Narhi, L.O., Boone, T.C. and Kenney, W.C., 1993. Cysteine 17 of 
recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J 
Protein Chem, 12: 525-31. 
Amaout, M.A., 1990. Leukocyte adhesion molecules deficiency: its structural basis, 
pathophysiology and implications for modulating the inflammatory response. Immunol Rev, 
114: 145-80. 
Amaout, M.A., Dana, N., Gupta, S.K., Tenen, D.G. and Fathallah, D.M., 1990. Point mutations 
impairing cell surface expression of the common beta subunit (CD 18) in a patient with 
leukocyte adhesion molecule (Leu-CAM) deficiency. J Clin Invest, 85: 977-81. 
19 
Avalos, B.R., Gasson, J.C., Hedvat, C., Quan, S.G., Baldwin, G.C., Weisbart, R.H., Williams, 
R.E., Golde, D.W. and DiPersio, J.F., 1990. Human granulocyte colony-stimulating factor: 
biologic activities and receptor characterization on hematopoietic cells and small cell lung 
cancer cell lines. Blood, 75: 851-7. 
Balazovich, K.J., Almeida, H.I. and Boxer, L.A., 1991. Recombinant human G-CSF and GM-
CSF prime human neutrophils for superoxide production through different signal 
transduction mechanisms. J Lab Clin Med, 118: 576-84. 
Bazan, J.F., 1990a. Haemopoietic receptors and helical cytokines. Immunol Today, 11: 350-4. 
Bazan, J.F., 1990b. Structural design and molecular evolution of a cytokine receptor 
superfamily. Proc Natl Acad Sci U S A, 87: 6934-8. 
Bociek, R.G. and Armitage, J.O., 1996. Hematopoietic growth factors [see comments]. CA 
Cancer J Clin, 46: 165-84. 
Brown, E.J., 1995. Phagocytosis. Bioessays, 17: 109-17. 
Buchta, R., 1990. Functional and biochemical properties of ovine neutrophils. Vet Immunol 
Immunopathol, 24: 97-112. 
Burgess, A.W. end Metcalf, D., 1980. The nature and action of granulocyte-macrophage colony 
stimulating factors. Blood, 56: 947-58. 
Cai, T.Q., Weston, P.G., Lund, L.A., Brodie, B., McKenna, D.J. and Wagner, W.C., 1994. 
Association between neutrophil functions and periparturient disorders in cows. Am J Vet 
Res, 55: 934-43. 
Cebon, J. and Layton, J., 1994. Measurement and clinical significance of circulating 
hematopoietic growth factor levels. Curr Opin Hematol, 1: 228-34. 
Cebon, J., Layton, J.E., Maher, D. and Morstyn, G., 1994. Endogenous haemopoietic growth 
factors in neutropenia and infection. Br J Haematol, 86: 265-74. 
Chatta, G.S., Price, T.H., Allen, R.C. and Dale, D.C., 1994. Effects of in vivo recombinant 
methionyl human granulocyte colony-stimulating factor on the neutrophil response and 
20 
peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood, 
84: 2923-9. 
Cheers, C., Haigh, A.M., Kelso, A., Metcalf, D., Stanley, E.R. and Young, A.M., 1988. 
Production of colony-stimulating factors (CSFs) during infection: separate determinations 
of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs. Infect Immun, 
56: 247-51. 
Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., Kris, M., Grous, J., 
Picozzi, v., Rausch, G. and et al., 1991. Reduction by granulocyte colony-stimulating factor 
of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer 
[see comments]. N Engl J Med, 325: 164-70. 
Dale, D.C., Liles, W.C., Surrmier, W.R. and Nelson, S., 1995. Review: granulocyte colony-
stimulating factor—role and relationships in infectious diseases. J Infect Dis, 172: 1061-75. 
Darnell, J.E., Jr., 1997. STATs and gene regulation. Science, 277: 1630-5. 
Demetri, G.D. and Griffin, J.D., 1991. Granulocyte colony-stimulating factor and its receptor. 
Blood, 78: 2791-808. 
Diederichs, K., Boone, T. and Karplus, P.A., 1991. Novel fold and putative receptor binding site 
of granulocyte-macrophage colony-stimulating factor. Science, 254: 1779-82. 
Ealick, S.E., Cook, W.J., Vijay-Kumar, S., Carson, M., Nagabhushan, T.L., Trotta, P.P. and 
Bugg, C.E., 1991. Three-dimensional structure of recombinant human interferon-gamma. 
Science, 252: 698-702. 
Emerson, S.G., Yang, Y.C., Clark, S.C. and Long, M.W., 1988. Human recombinant 
granulocyte-macrophage colony stimulating factor and interleukin 3 have overlapping but 
distinct hematopoietic activities. J Clin Invest, 82: 1282-7. 
Etzioni, A., Frydman, M., Pollack, S., Avidor, I., Phillips, M.L., Paulson, J.C. and Gershoni-
Baruch, R., 1992. Brief report: recurrent severe infections caused by a novel leukocyte 
adhesion deficiency. N Engl J Med, 327: 1789-92. 
21 
Fearon, D.T. and Lcxksley, R.M., 1996. The instructive role of innate immunity in the acquired 
immune response. Science, 272: 50-3. 
Ferrante, A., Martin, A.J., Bates, EJ., Goh, D.H., Harvey, D.P., Parsons, D., Rathjen, D.A., 
Russ, G. and Dayer, J.M., 1993. Killing of Staphylococcus aureus by tumor necrosis 
factor-alpha-activated neutrophils. The role of serum opsonins, integrin receptors, 
respiratory burst, and degranulation. J Immunol, 151:4821-8. 
Ferrante, A., Nandoskar, M., Bates, E.J., Goh, D.H. and Beard, LJ., 1988a. Tumour necrosis 
factor beta (lymphotoxin) inhibits locomotion and stimulates the respiratory burst and 
degranulation of neutrophils. Immunology, 63: 507-12. 
Ferrante, A., Nandoskar, M., Walz, A., Goh, D.H. and Kowanko, I.C., 1988b. Effects of tumour 
necrosis factor alpha and interleukin-1 alpha and beta on human neutrophil migration, 
respiratory burst and degranulation. Int Arch Allergy Appl Immunol, 86: 82-91. 
Fibbe, W.E., van Damme, J., Billiau, A., Goselink, H.M., Voogt, PJ., van Eeden, G., Ralph, P., 
Altrock, B.W. and Falkenburg, J.H., 1988. Interleukin 1 induces human marrow stromal 
cells in long-term culture to produce granulocyte colony-stimulating factor and macrophage 
colony-stimulating factor. Blood, 71: 430-5. 
Fuji], I., Nagahara, Y., Yamasaki, M., Yokoo, Y., Itoh, S. and Hirayama, N., 1997. Structure of 
KW-2228, a tailored human granulocyte colony-stimulating factor with enhanced biological 
activity and stability. FEBS Lett, 410: 131-5. 
Fukunaga, R., Ishizaka-Dceda, E., Pan, C.X., Seto, Y. and Nagata, S., 1991. Functional domains 
of the granulocyte colony-stimulating factor receptor. Embo J, 10: 2855-65. 
Fukunaga, R., Ishizaka-Ikeda, E., Seto, Y. and Nagata, S., 1990a. Expression cloning of a 
receptor for murine granulocyte colony-stimulating factor. Cell, 61: 341-50. 
Fukunaga, R., Seto, Y., Mizushima, S. and Nagata, S., 1990b. Three different mRNAs encoding 
human granulocyte colony-stimulating factor receptor. Proc Natl Acad Sci U S A, 87: 8702-
6. 
22 
Gabay, J.E., 1988. Microbicidal mechanisms of phagocytes. CurrOpin Immunol, 1: 36-40. 
Gabrilove, J.L., 1992. Clinical applications of granulocyte colony stimulating factor (G-CSF). 
Growth Factors, 6: 187-91. 
Garland, J.M., Quesenberry, p.j., and Hilton, D.J., 1997. Colony-stimulating factors : molecular 
and cellular biology. Marcel Deckker, New York, p. 203-225. 
Gorgen, I., Hartung, T., Leist, M., Niehorster, M., Tiegs, G., Uhlig, S., Weitzel, F. and Wendel, 
A., 1992. Granulocyte colony-stimulating factor treatment protects rodents against 
lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-
alpha. J Immunol, 149: 918-24. 
Gough, N.M., Gough, J., Metcalf, D., Kelso, A., Grail, D., Nicola, N.A., Burgess, A.W. and 
Dunn, A.R., 1984. Molecular cloning of cDNA encoding a murine haematopoietic growth 
regulator, granulocyte-macrophage colony stimulating factor. Nature, 309: 763-7. 
Goya, T., Torisu, M., Doi, F. and Yoshida, T., 1993. Effects of granulocyte colony stimulating 
factor and monobactam antibiotics (Aztreonam) on neutrophil functions in sepsis. Clin 
Immunol Immunopathol, 69: 278-84. 
Hammond, W.P., Csiba, E., Canin, A., Hockman, H., Souza, L.M., Layton, J.E. and Dale, D.C., 
1991. Chronic neutropenia. A new canine model induced by human granulocyte colony-
stimulating factor. J Clin Invest, 87: 704-10. 
Han, S.W., Ramesh, N. and Osborne, W.R., 1996. Cloning and expression of the cDNA 
encoding rat granulocyte colony-stimulating factor. Gene, 175: 101-4. 
Hansen, P.B., Kjaersgaard, E., Johnsen, H.E., Gram, J., Pedersen, M., Nikolajsen, K. and 
Hansen, N.E., 1993. Different membrane expression of CDl lb and CD 14 on blood 
neutrophils following in vivo administration of myeloid growth factors [published erratum 
appears in Br J Haematol 1994 Jan;86(l):240]. Br J Haematol, 85: 50-6. 
Heidari, M., and Kehrli, M£., Jr., 2000. Cloning, sequencing, and analysis of cDNA encoding 
bovine granulocyte-colony stimulating factor. Vet Immunol Immunopath, 73: 183-191. 
23 
Hill, C.P., Osslund, T.D. and Eisenberg, D., 1993. The structure of granulocyte-colony-
s t i m u l a t i n g  f a c t o r  a n d  i t s  r e l a t i o n s h i p  t o  o t h e r  g r o w t h  f a c t o r s .  P r o c  N a t l  A c a d  S c i  U S A ,  
90: 5167-71. 
Hommes, D.W., Meenan, J., Dijkhuizen, S., Ten Kate, FJ., Tytgat, G.N. and Van Deventer, S J., 
1996. Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in 
experimental colitis. Clin Exp Immunol, 106: 529-33. 
Horan, T., Wen, J., Narhi, L., Parker, V., Garcia, A., Arakawa, T. and Philo, J., 1996. 
Dimerization of the extracellular domain of granuloycte-colony stimulating factor receptor 
by ligand binding: a monovalent ligand induces 2:2 complexes. Biochemistry, 35:4886-96. 
Ishikawa, M., Djima, H., Satake-Ishikawa, R., Tsumura, H., Iwamatsu, A., Kadoya, T., Shimada, 
Y., Fukamachi, H., Kobayashi, K., Matsuki, S. and et al., 1992. The substitution of cysteine 
17 of recombinant human G-CSF with alanine greatly enhanced its stability. Cell Struct 
Funct, 17: 61-5. 
Jacobs, K., Shoemaker, C., Rudersdorf, R., Neill, S.D., Kaufman, R.J., Mufson, A., Seehra, J., 
Jones, S.S., Hewick, R., Fritsch, E.F. and et al., 1985. Isolation and characterization of 
genomic and cDNA clones of human erythropoietin. Nature, 313: 806-10. 
Kanazawa, M., Ishizaka, A., Hasegawa, N., Suzuki, Y. and Yokoyama, T., 1992. Granulocyte 
colony-stimulating factor does not enhance endotoxin-induced acute lung injury in guinea 
pigs. Am Rev Respir Dis, 145: 1030-5. 
Kawasaki, E.S., Ladner, M.B., Wang, A.M., Van Arsdell, J., Warren, M.K., Coyne, M. Y., 
Schweickart, V.L., Lee, M.T., Wilson, K J., Boosman, A. and et al., 1985. Molecular cloning 
of a complementary DNA encoding human macrophage-specific colony-stimulating factor 
(CSF-1). Science, 230: 291-6. 
Kayashima, S., Tsuru, S., Hata, N. and Rokutanda, M., 1993. Therapeutic effect of granulocyte 
colony-stimulating factor (G-CSF) on the protection against Listeria infection in SCID 
mice. Immunology, 80: 471-6. 
24 
Kehrii, M.E., Jr., Shuster, D.E., Stabel, J.R., Stevens, M.G., Thurston, J. R. and Daley, M., 
1993. Effects of recombinant bovine granuiocyte-macrophage-colony stimulating factor 
administration on the bovine immune system and resistance to inflammatory challenge with 
Escherichia coli. J Leukocyte Bioi., 54: 60-65. 
Kehrii, M.E., Jr., Goff, J.P., Stevens, M.G. and Boone, T.C., 1991. Effects of granulocyte 
colony-stimulating factor administration to periparturient cows on neutrophils and bacterial 
shedding. J Dairy Sci, 74: 2448-58. 
Kehrii, M.E., Jr., Nonnecke, B.J. and Roth, J.A., 1989a. Alterations in bovine lymphocyte 
function during the periparturient period. Am J Vet Res, 50: 215-20. 
Kehrii, M.E., Jr., Nonnecke, B.J. and Roth, J.A., 1989b. Alterations in bovine neutrophil 
function during the periparturient period. Am J Vet Res, 50: 207-14. 
Kehrii, M.E., Jr., Schmalstieg, F.C., Anderson, D.C., Van der Maaten, M.J., Hughes, B.J., 
Ackermann, M.R., Wilhelmsen, C.L., Brown, G.B., Stevens, M.G. and Whetstone, C.A., 
1990. Molecular definition of the bovine granulocytopathy syndrome: identiHcation of 
deficiency of the Mac-1 (CDl lb/CD18) glycoprotein. Am J Vet Res, 51: 1826-36. 
Kitagawa, S., Yuo, A., Souza, L.M., Saito, M., Miura, Y. and Takaku, F., 1987. Recombinant 
human granulocyte colony-stimulating factor enhances superoxide release in human 
granulocytes stimulated by the chemotactic peptide. Biochem Biophys Res Commun, 144: 
1143-6. 
Kittler, E.L., McGrath, H., Temeles, D., Crittenden, R.B., Kister, V.K. and Quesenberry, P.J., 
1992. Biologic significance of constitutive and subliminal growth factor production by bone 
marrow stroma. Blood, 79: 3168-78. 
Krantz, S.B., 1991. Erythropoietin. Blood, 77: 419-34. 
Kubota, N., Orita, T., Hattori, K., Oh-eda, M., Ochi, N. and Yamazaki, T., 1990. Structural 
characterization of natural and recombinant human granulocyte colony-stimulating factors. J 
Biochem (Tokyo), 107: 486-92. 
25 
Kuga, T., Komatsu, Y., Yamasaki, M., Sekine, S., Miyaji, H., Nishi, T., Sato, M., Yokoo, Y., 
Asano, M., Okabe, M. and et al., 1989. Mutagenesis of human granulocyte colony 
stimulating factor. Biochem Biophys Res Commun, 159: 103-11. 
Kulmburg, P., Radke, M., Mezes, B., Mertelsmann, R. and Rosenthal, F.M., 1997. Cloning and 
sequence analysis of the immediate promoter region and cDNA of porcine granulocyte 
colony-stimulating factor. Gene, 197: 361-5. 
Ladner, M.B., Martin, G.A., Noble, J.A., Wittman, V.P., Wanen, M.K., McGiogan, M. and 
Stanley, E.R., 1988. cDNA cloning and expression of murine macrophage colony-
stimulating factor from L929 cells. Proc Natl Acad Sci U S A, 85: 6706-10. 
Layton, J.E., Shimamoto, G., Osslund, T., Hammacher, A., Smith, D.K., Treutlein, H.R. and 
Boone, T., 1999. Interaction of granulocyte colony-stimulating factor (G-CSF) with its 
receptor. Evidence that Glul9 of G-CSF interacts with Arg288 of the receptor. J Biol Chem, 
274: 17445-51. 
Leong, S.R., Flaggs, G.M., Lawman, M.J. and Gray, P.W., 1989. Cloning and expression of the 
cDNA for bovine granulocyte-macrophage colony-stimulating factor. Vet Immunol 
Immunopathol, 21: 261-78. 
Lieschke, G.J., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., Fowler, K.J., Basu, 
S., Zhan, Y.F. and Dunn, A.R., 1994. Mice lacking granulocyte colony-stimulating factor 
have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and 
impaired neutrophil mobilization. Blood, 84: 1737-46. 
Liles, W.C., Roger, E. R., and Dale, D.C., 1994. Differential regulation of human neutrophil 
surface expression of CD14, CDl lb, CD18, and L-selectin following the administration of 
G-CSF in vivo and in vitro. Clinical Research, 42: 304A. 
Lindemann, A., Riedel, D., Oster, W., Ziegler-Heitbrock, H.W., Mertelsmann, R. and Herrmann, 
F., 1989. Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by 
human polymorphonuclear leukocytes. J Clin Invest, 83: 1308-12. 
26 
Lopez, A., Maxie, M.G., Ruhnke, L., Savan, M. and Thomson, R.G., 1986. Cellular 
inflammatory response in the lungs of calves exposed to bovine viral diarrhea virus. 
Mycoplasma bovis, and Pasteurella haemolytica. Am J Vet Res, 47: 1283-6. 
Lopez, A.F., To, L.B., Yang, Y.C., Gamble, J.R., Shannon, MJ., Bums, G.F., Dyson, P.G., 
Jutmer, C.A., Clark, S. and Vadas, M.A., 1987. Stimulation of proliferation, differentiation, 
and function of human cells by primate interleukin 3. Proc Natl Acad Sci U S A, 84: 2761-
5. 
Lovejoy, B., Cascio, D. and Eisenberg, D., 1993. Crystal structure of canine and bovine 
granulocyte-colony stimulating factor (G-CSF). J Mol Biol, 234: 640-53. 
Lu, H.S., Boone, T.C., Souza, L.M. and Lai, P.H., 1989. Disulfide and secondary structures of 
recombinant human granulocyte colony stimulating factor. Arch Biochem Biophys, 268: 
81-92. 
Lu, H.S., Clogston, C.L., Narhi, L.O., Merewether, L.A., Pearl, W.R. and Boone, T.C., 1992. 
Folding and oxidation of recombinant human granulocyte colony stimulating factor 
produced in Escherichia coli. Characterization of the disulfide-reduced intermediates and 
cysteine—serine analogs. J Biol Chem, 267: 8770-7. 
Lundblad, R., Nesland, J.M. and Giercksky, K.E., 1996. Granulocyte colony-stimulating factor 
improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis 
factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Crit Care Med, 24: 820-
6. 
Mempel, K., Pietsch, T., Menzel, T., Zeidler, C. and Welte, K., 1991. Increased semm levels of 
granulocyte colony-stimulating factor in patients with severe congenital neutropenia. Blood, 
77: 1919-22. 
Messner, H. A., Yamasaki, K., Jamal, N., Minden, M.M., Yang, Y.C., Wong, G.G. and Clark, 
S.C., 1987. Growth of human hemopoietic colonies in response to recombinant gibbon 
27 
interleukin 3: comparison with human recombinant granulocyte and granulocyte-
macrophage colony-stimulating factor. Proc Natl Acad Sci U S A, 84: 6765-9. 
Metcalf, D., 1985. The granulocyte-macrophage colony-stimulating factors. Science, 229: 16-
22. 
Metcalf, D., 1986. The molecular biology and functions of the granulocyte-macrophage colony-
stimulating factors. Blood, 67: 257-67. 
Metcalf, D., 1993. Hematopoietic regulators: redundancy or subtlety? Blood, 82: 3515-23. 
Metcalf, D. and Nicola, N.A., 1983. Proliferative effects of purified granulocyte colony-
stimulating factor (G-CSF) on normal mouse hemopoietic cells. J Cell Physiol, 116: 198-
206. 
Ming, W.J., Bersani, L. and Mantovani, A., 1987. Tumor necrosis factor is chemotactic for 
monocytes and polymorphonuclear leukocytes. J Immunol, 138: 1469-74. 
Monaco, L., Tagliabue, R., Giovanazzi, S., Bragonzi, A. and Soria, M.R., 19%. Expression of 
recombinant human granulocyte colony-stimulating factor in CHO dhfr- cells: new insights 
into the in vitro ampUHcation expression system. Gene, 180: 145-50. 
Mooney, D.P., Gamelli, R.L., O'Reilly, M. and Hebert, J.C., 1988. Recombinant human 
granulocyte colony-stimulating factor and Pseudomonas bum wound sepsis. Arch Surg, 
123: 1353-7. 
Moore, M.A., 1988. The use of hematopoietic growth and differentiation factors for bone 
marrow stimulation. Important Adv Oncol, 31-54. 
Morstyn, G., Campbell, L., Souza, L.M., Alton, N.K., Keech, J., Green, M., Sheridan, W., 
Metcalf, D. and Fox, R., 1988. Effect of granulocyte colony stimulating factor on 
neutropenia induced by cytotoxic chemotherapy. Lancet, 1: 667-72. 
Motoji, T., Watanabe, M., Uzumaki, HL, Kusaka, M., Fukamachi, H., Shimosaka, A., Oshimi, K. 
and Mizoguchi, H., 1991. Granulocyte colony-stimulating factor (G-CSF) receptors on 
28 
acute myeioblastic leukaemia ceils and their relationship with the proliferative response to 
G-CSF in clonogenic assay. Br J Haematol, 77: 54-9. 
Mott, H.R., Driscoll, P.C., Boyd, J., Cooke, R.M., Weir, M.P. and Campbell, I.D., 1992. 
Secondary structure of human interleukin 2 from 3D heteronuclear NMR experiments. 
Biochemistry, 31: 7741-4. 
Nagahata, H., Makino, S., Takeda, S., Takahashi, H. and Noda, H., 1988. Assessment of 
neutrophil function in the dairy cow during the perinatal period. Zentralbl Veterinarmed [B], 
35: 747-51. 
Nagata, S. and Fukunaga, R., 1991. Granulocyte colony-stimulating factor and its receptor. 
Prog Growth Factor Res, 3: 131-41. 
Nagata, S., Tsuchiya, M., Asano, S., Kaziro, Y., Yamazaki, T., Yamamoto, O., Hirata, Y., Kubota, 
N., Oheda, M., Nomura, H. and et al., 1986a. Molecular cloning and expression of cDNA 
for human granulocyte colony-stimulating factor. Nature, 319: 415-8. 
Nagata, S., Tsuchiya, M., Asano, S., Yamamoto, O., Hirata, Y., Kubota, N., Oheda, M., Nomura, 
H. and Yamazaki, T., 1986b. The chromosomal gene structure and two mRNAs for human 
granulocyte colony-stimulating factor. Embo J, 5: 575-81. 
Nathan, C.F., 1989. Respiratory burst in adherent human neutrophils: triggering by colony-
stimulating factors CSF-GM andCSF-G. Blood, 73: 301-6. 
Neidhart, J., Mangalik, A., Kohler, W., Stidley, C., Saiki, J., Duncan, P., Souza, L. and Downing, 
M., 1989. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in 
patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin 
Oncol, 7: 1685-92. 
Nicholson, S.E., Novak, U., Ziegler, S.F. and Layton, J.E., 1995. Distinct regions of the 
granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of 
the signaling molecules JAK2, Stat3, and p42, p44MAPK. Blood, 86: 3698-704. 
29 
Nickerson, S.C., Owens, W£. and Watts, J.L., 1989. Effects of recombinant granulocyte 
colony-stimulating factor on Staphylococcus aureus mastitis in lactating dairy cows. 
J Dairy Sci, 72: 3286-94. 
Nicola, N.A., Begley, C.G. and Metcalf, D., 1985. Identiflcation of the human analogue of a 
regulator that induces differentiation in murine leukaemic cells. Nature, 314; 625-8. 
Nicola, N.A. and Metcalf, D., 1982. Analysis of purified fetal liver hemopoietic progenitor cells 
in liquid culture. J Cell Physiol, 112: 257-64. 
Nicola, N.A. and Metcalf, D., 1984. Binding of the differentiation-inducer, granulocyte-colony-
stimulating factor, to responsive but not unresponsive leukemic cell lines. Proc Natl Acad 
SciUS A, 81:3765-9. 
Nicola, N.A., Metcalf, D., Johnson, G.R. and Burgess, A.W., 1979. Separation of functionally 
distinct human granulocyte-macrophage colony-stimulating factors. Blood, 54: 614-27. 
Nomura, H., Imazeki, I., Oheda, M., Kubota, N., Tamura, M., Ono, M., Ueyama, Y. and Asano, 
S., 1986. Purification and characterization of human granulocyte colony- stimulating factor 
(G-CSF). Embo J, 5: 871-6. 
O'Brien, P.M., Seow, H.F., Rothel, J.S. and Wood, P.R., 1994. Cloning and sequencing of an 
ovine granulocyte colony-stimulating factor cDNA. DNA Seq, 4: 339-42. 
O'Reilly, M., Silver, G.M., Greenhalgh, D.G., Gamelli, R.L., Davis, J.H. and Hebert, J.C., 1992. 
Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. 
J Trauma, 33: 679-82. 
Ogle, J.D., Noel, J.G., Sramkoski, R.M., Ogle, C.K. and Alexander, J.W., 1990. The effects of 
cytokines, platelet activating factor, and arachidonate metabolites on C3b receptor (CRl, 
CD35) expression and phagocytosis by neutrophils. Cytokine, 2: 447-55. 
Oh-eda, M., Hasegawa, M., Hattori, K., Kuboniwa, H., Kojima, T., Orita, T., Tomonou, K., 
Yamazaki, T. and Ochi, N., 1990. O-Iinked sugar chain of human granulocyte colony-
30 
stimulating factor protects it against polymerization and denaturation allowing it to retain its 
biological activity. J Biol Chem, 265: 11432-5. 
Ohsaka, A. and Saionji, K., 1998. In vivo administration of granulocyte colony-stimulating 
factor increases the surface expression of sialyl-Lewis(x) on neutrophils in healthy 
volunteers. Acta Haematol, 100: 187-90. 
Ohsaka, A., Saionji, K., Sato, N., Mori, T., Ishimoto, K. and Inamatsu, T., 1993. Granulocyte 
colony-stimulating factor down-regulates the surface expression of the human leucocyte 
adhesion molecule-1 on human neutrophils in vitro and in vivo. Br J Haematol, 84: 574-80. 
Okabe, M., Asano, M., Kuga, T., Komatsu, Y., Yamasaki, M., Yokoo, Y., Itoh, S., Morimoto, M. 
and Oka, T., 1990. In vitro and in vivo hematopoietic effect of mutant human granulocyte 
colony-stimulating factor [see conmients]. Blood, 75: 1788-93. 
Osslund, T., and Boone, T., 1994. biochemistry and structure of filgrastim (r-metHuG-CSF). 
Marcel Dekker, New York, pp. 23-31. 
Pandit, J., Bohm, A., Jancarik, J., Halenbeck;, R., Koths, K. and Kim, S.H., 1992. Three-
dimensional structure of dimeric human recombinant macrophage colony-stimulating factor. 
Science, 258: 1358-62. 
Park, L.S., Waldron, P.E., Friend, D., Sassenfeid, H.M., Price, V., Anderson, D., Cosman, D., 
Andrews, R.G., Bernstein, I.D. and Urdal, D.L., 1989. Interleukin-3, GM-CSF, and G-CSF 
receptor expression on cell iines and primary leukemia cells: receptor heterogeneity and 
relationship to growth factor responsiveness. Blood, 74: 56-65. 
Platzer, E., Welte, K., Gabrilove, J.L., Lu, L., Harris, P., Mertelsmann, R. and Moore, M.A., 
1985. Biological activities of a human pluripotent hemopoietic colony stimulating factor on 
normal and leukemic cells. J Exp Med, 162: 1788-801. 
Rambaldi, A., Young, D.C. and Griffin, J.D., 1987. Expression of the M-CSF (CSF-1) gene by 
human monocytes. Blood, 69: 1409-13. 
31 
Rapoport, A.P., Abboud, C.N. and DiPersio, J.F., 1992. Granulcx:yte-macrophage colony-
stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor 
biology, signal transduction, and neutrophil activation. Blood Rev, 6:43-57. 
Redfield, C., Smith, LJ., Boyd, J., Lawrence, G.M., Edwards, R.G., Smith, R.A. and Dobson, 
C.M., 1991. Secondary structure and topology of human interleukin 4 in solution. 
Biochemistry, 30; 11029-35. 
Renshaw, H.W. and Davis, W.C., 1979. Canine granulocytopathy syndrome: an inherited 
disorder of leukocyte function. Am J Pathol, 95: 731-44. 
Roilides, E., Uhlig, K., Venzon, D., Pi2KO, P.A. and Walsh, T.J., 1993. Prevention of 
corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced 
damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and 
gamma interferon. Infect Immun, 61:4870-7. 
Roilides, E., Walsh, TJ., Pizzo, P.A. and Rubin, M., 1991. Granulocyte colony-stimulating 
factor enhances the phagocytic and bactericidal activity of normal and defective human 
neutrophils. J Infect Dis, 163: 579-83. 
Saad, A.M., Concha, C. and Astrom, G., 1989. Alterations in neutrophil phagocytosis and 
lymphocyte blastogenesis in dairy cows around parturition. Zentralbl Veterinarmed [B], 36: 
337-45. 
Satake-Ishikawa, R., Ishikawa, M., Okada, Y., Kakitani, M., Kawagishi, M., Matsuki, S. and 
Asano, K., 1992. Chemical modification of recombinant human granulocyte colony-
stimulating factor by polyethylene glycol increases its biological activity in vivo. Cell Struct 
Funct, 17: 157-60. 
Senda, T., Shimazu, T., Matsuda, S., Kawano, G., Shimizu, H., Nakamura, K.T. and Mitsui, Y., 
1992. Three-dimensional crystal structure of recombinant murine interferon-beta. Embo J, 
11: 3193-201. 
32 
Seow, W.K., Thong, Y.H. and Ferrante, A., 1987. Macrophage-neutrophil interactions: 
contrasting effects of the monokines interleukin-1 and tumour necrosis factor (cachectin) on 
human neutrophil adherence. Immunology, 62: 357-61. 
Serushago, B.A., Yoshikai, Y., Handa, T., Mitsuyama, M., Muramori, K. and Nomoto, K., 1992. 
Effect of recombinant human granulocyte colony-stimulating factor (rh G-CSF) on murine 
resistance against Listeria monocytogenes. Immunology, 75: 475-80. 
Shalaby, M.R., Palladino, M.A., Jr., Hirabayashi, S£., Eessalu, T£., Lewis, GX)., Shepard, 
H.M. and Aggarwal, B.B., 1987. Receptor binding and activation of polymorphonuclear 
neutrophils by tumor necrosis factor-alpha. J Leukoc Biol, 41: 196-204. 
Shimoda, K., Iwasaki, H., Okamura, S., Ohno, Y., Kubota, A., Arima, F., Otsuka, T. and Niho, 
Y., 1994. G-CSF induces tyrosine phosphorylation of the JAK2 protein in the human 
myeloid G-CSF responsive and proliferative cells, but not in mature neutrophils. Biochem 
Biophys Res Commun, 203: 922-8. 
Shimoda, K., Okamura, S., Harada, N., Kondo, S., Okamura, T. and Niho, Y., 1993. 
Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. 
J Clin Invest, 91: 1310-3. 
Silver, G.M., Gamelli, R.L. and O'Reilly, M., 1989. The beneficial effect of granulocyte colony-
stimulating factor (G-CSF) in combination with gentamicin on survival after Pseudomonas 
bum wound infection. Surgery, 106:452-5; discussion 455-6. 
Smith, W.S., Sumnicht, G.E., Shaipe, R.W., Samuelson, D. and Millard, F.E., 1995. 
Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a 
randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and 
multisystem organ failure. Blood, 86: 1301-9. 
Souza, L.M., Boone, T.C., Gabrilove, J., Lai, P.H., Zsebo, K.M., Murdock, D.C., Chazin, V.R., 
Bruszewski, J., Lu, H., Chen, K.K. and et al., 1986. Recombinant human granulocyte 
colony-stimulating factor: effects on normal and leukemic myeloid cells. Science, 232: 61-5. 
33 
Spertini, O., Kansas, G.S., Munro, J.M., Griffin, J.D. and Tedder, T.F., 1991. Regulation of 
leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. 
Nature, 349: 691-4. 
Steinbeck, M.J. and Roth, J.A., 1989. Neutrophil activation by recombinant cytokines. Rev 
Infect Dis, 11: 549-68. 
Stevens, P.K. and Czuprynski, C.J., 1996. Pasteurella haemolytica leukotoxin induces bovine 
leukocytes to undergo morphologic changes consistent with apoptosis in vitro. Infect 
Immun, 64: 2687-94. 
Tamura, M., Hattori, K., Nomura, H., Oheda, M., Kubota, N., Imazeki, I., Ono, M., Ueyama, Y., 
Nagata, S., Shirafuji, N. and et al., 1987. Induction of neutrophilic granulocytosis in mice by 
administration of purified human native granulocyte colony-stimulating factor (G-CSF). 
Biochem BiophyS ReS Commun, 142: 454-60. 
Tanaka, H., Okada, Y., Kawagishi, M. and Tokiwa, T., 1989. Pharmacokinetics and 
pharmacodynamics of recombinant human granulocyte-colony stimulating factor after 
intravenous and subcutaneous administration in the rat. J Pharmacol Exp Ther, 251: 1199-
203. 
Tanaka, H., Tanaka, Y., Shinagawa, K., Yamagishi, Y., Ohtaki, K. and Asano, K., 1997. Three 
types of recombinant human granulocyte colony-stimulating factor have equivalent 
biological activities in monkeys. Cytokine, 9: 360-9. 
Tian, S.S., Lamb, P., Seidel, H.M., Stein, R.B. and Rosen, J., 1994. Rapid activation of the 
STAT3 transcription factor by granulocyte colony-stimulating factor. Blood, 84: 1760-4. 
Tian, S.S., Tapley, P., Sincich, C., Stein, R.B., Rosen, J. and Lamb, P., 1996. Multiple signaling 
pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, 
STATS, and/or STAT3 are required for regulation of three distinct classes of immediate 
early genes. Blood, 88: 4435-44. 
34 
Tsuchiya, M., Asano, S., Kaziro, Y. and Nagata, S., 1986. Isolation and characterization of the 
cDNA for murine granulocyte colony-stimulating factor. Proc Natl Acad Sci USA, 83: 
7633-7. 
Tsuchiya, M., Kaziro, Y. and Nagata, S., 1987. The chromosomal gene structure for murine 
granulocyte colony-stimulating factor. Eur J Biochem, 165: 7-12. 
Turzanski, J., Crouch, S.P., Fletcher, J. and Hunter, A., 1997. Ex vivo neutrophil function in 
response to three different doses of glycosylated rHuG-CSF (Lenograstim). Br J Haematol, 
96: 46-54. 
Tweardy, D.J., Mott, PI., and Glazer, E.W., 1990. Monokine modulation of human astroglial 
cell production of granulocyte colony-stimulating factor and granulocyte-macrophage 
colony-stimulating factor. I. Effects of IL-1 alpha and IL-beta. J Immunol, 144: 2233-41. 
Ulich, T.R., del Castillo, J., Watson, L.R., Yin, S.M. and Gamick, M.B., 1990. In vivo 
hematologic effects of recombinant human macrophage colony-stimulating factor. Blood, 
75: 846-50. 
Uzumaki, H., Okabe, T., Sasaki, N., Hagiwara, K., Takaku, F., Tobita, M., Yasukawa, K., Ito, S. 
and Umezawa, Y., 1989. Identification and characterization of receptors for granulocyte 
colony-stimulating factor on human placenta and trophoblastic cells. Proc Natl Acad Sci U 
S A, 86: 9323-6. 
Vellenga, E., Rambaldi, A., Ernst, TJ., Ostapovicz, D. and Griffin, J.D., 1988. Independent 
regulation of M-CSF and G-CSF gene expression in human monocytes. Blood, 71: 1529-
32. 
Wang, J.M., Chen, Z.G., Colella, S., Bonilla, M.A., Welte, K., Bordignon, C. and Mantovani, A., 
1988. Chemotactic activity of recombinant human granulocyte colony-stimulating factor. 
Blood, 72: 1456-60. 
35 
Welte, K., Platzer, E., Lu, L., Gabrilove, JJ-., Levi, E., Mertelsmann, R. and Moore, M.A., 1985. 
Purification and biochemical characterization of human pluripotent hematopoietic colony-
stimulating factor. Proc Natl Acad Sci USA, 82: 1526-30. 
Wewers, M.D., Rinehart, JJ., She, Z.W., Herzyk, D.J., Hummel, M.M., Kinney, P.A. and 
Davis, W.B., 1990. Tumor necrosis factor infusions in humans prime neutrophils for 
hypochlorous acid production. Am J Physiol, 259: L276-82. 
Wlodaver, A., Pavlovsky, A. and Gustchina, A., 1992. Crystal structure of human recombinant 
interleukin-4 at 2.25 A resolution. FEBS Lett, 309: 59-64. 
Woll, P.J., Hodgetts, J., Lomax, L., Bildet, F., Cour-Chabemaud, V. and Thatcher, N., 1995. Can 
cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A 
randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol, 13: 652-
9. 
Wong, G.G., Temple, P.A., Leary, A.C., Witek-Giannotti, J.S., Yang, Y.C., Ciarletta, A.B., 
Chung, M., Murtha, P., Kriz, R., Kaufman, R.J. and et al., 1987. Human CSF-1: molecular 
cloning and expression of 4-kb cDNA encoding the human urinary protein. Science, 235: 
1504-8. 
Wong, G.G., Witek, J.S., Temple, P. A., Wilkens, K.M., Leary, A.C., Luxenberg, D.P., Jones, 
S.S., Brown, E.L., Kay, R.M., Orr, E.C. andet al., 1985. Human GM-CSF: molecular 
cloning of the complementary DNA and purification of the natural and recombinant 
proteins. Science, 228: 810-5. 
Yamasaki, M., Asano, M., Okabe, M., Morimoto, M. and Yokoo, Y., 1994. Modification of 
recombinant human granulocyte colony-stimulating factor (rhG-CSF) and its derivative ND 
28 with polyethylene glycol. J Biochem (Tokyo), 115: 814-9. 
Yang, Y.C., Ciarletta, A.B., Temple, P.A., Chung, M.P., Kovacic, S., Witek-Giannotti, J.S., Leary, 
A.C., Kriz, R., Donahue, R.E., Wong, G.G. and et al., 1986. Human IL-3 (multi-CSF): 
36 
identification by expression cloning of a novel hematopoietic growth factor related to 
murine IL-3. Cell, 47: 3-10. 
Yasuda, H., Ajiki, Y., Shimozato, T., Kasahara, M., Kawada, H., Iwata, M. and Shimizu, K., 
1990. Therapeutic efficacy of granulocyte colony-stimulating factor alone and in 
combination with antibiotics against Pseudomonas aeruginosa infections in mice. Infect 
Immun, 58: 2502-9. 
Yong, K.L. and Linch, D.C., 1992. Differential effects of granulocyte- and granulocyte-
macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro 
and in vivo. Eur J Haematol, 49: 251-9. 
Yuo, A., Kitagawa, S., Ohsaka, A., Ohta, M., Miyazono, K., Okabe, T., Urabe, A., Saito, M. and 
Takaku, F., 1989. Recombinant human granulocyte colony-stimulating factor as an activator 
of human granulocytes: potentiation of responses triggered by receptor-mediated agonists 
and stimulation of C3bi receptor expression and adherence. Blood, 74: 2144-9. 
Ziegler, S.F., Bird, T.A., Morella, K.K., Mosley, B., Gearing, D.P. and Baumann, H., 1993. 
Distinct regions of the human granulocyte-colony-stimulating factor receptor cytoplasmic 
domain are required for proliferation and gene induction. Mol Cell Biol, 13: 2384-90. 
Zink, T., Ross, A., Luers, K., Cieslar, C., Rudolph, R. and Holak, T.A., 1994. Structure and 
dynamics of the human granulocyte colony-stimulating factor determined by NMR 
spectroscopy. Loop mobility in a four-helix-bundle protein. Biochemistry, 33: 8453-63. 
Zoellner, H., Filonzi, E.L., Stanton, H.R., Layton, J.E. and Hamilton, J.A., 1992. Human arterial 
smooth muscle cells synthesize granulocyte colony-stimulating factor in response to 
interleukin-1 alpha and tumor necrosis factor-alpha. Blood, 80: 2805-10. 
Zsebo, K.M., Cohen, A.M., Murdock, D.C., Boone, T.C., Inoue, H., Chazin, V.R., Hines, D. and 
Souza, L.M., 1986. Recombinant human granulocyte colony stimulating factor molecular 
and biological characterization. Immunobiology, 172: 175-84. 
37 
Zsebo, K.M., Yuschenkoff, V.N., Schiffer, S., Chang, D., McCall, E., Dinarello, C.A., Brown, 
M.A., Altrock, B. and Bagby, G.C., Jr., 1988. Vascular endothelial cells and granulopoiesis: 
interleukin-1 stimulates release of G-CSF and GM-CSF. Blood, 71: 99-103. 
38 
CLONING, SEQUENCING, AND ANALYSIS OF CDNA 
ENCODING BOVINE GRANULOCYTE-COLONY 
STIMULATING FACTOR 
A paper published in the Journal of Veterinary Immunology and Immunopathology 
Mohanunad Heidari and Marcus E. Kehrii, Jr. 
Abstract 
Neutrophils play a critical role in defending against bacterial infections. Hematopoietic 
growth factors are a class of regulatory cytokines that are required for stimulation, proliferation, 
and differentiation of blood cells. Granulocyte colony stimulating factor (G-CSF) is a cytokine 
that induces proliferation and maturation of precursor myeloid cells in the bone marrow into 
fully differentiated neutrophils. G-CSF also modulates the functional activity of mature 
neutrophils. Treatment with G-CSF significantly enhances neutrophil phagocytic activity and 
killing of bacteria and fungi. We have isolated and sequenced a cDNA clone encoding bovine 
G-CSF (bG-CSF) from an endothelial cell cDNA library using primers designed from ovine 
G-CSF. The full length cDNA is 1460 nucleotides long with 585 nucleotides comprising the 
open reading frame. Sequence analysis shows 95% identity with ovine, 89% with porcine, 85% 
with human, and 76% with murine G-CSF. The deduced G-CSF protein consists of 174 amino 
acids with 95% identity to ovine, 86% to porcine, 81% to human, and 71% to murine. The 
signal peptide of G-CSF is 21 amino acids long which is 9 amino acids shorter than that of 
human and murine G-CSF. 
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1. Introduction 
Colony stimulating factors (CSFs) are a group of glycoproteins that regulate proliferation 
and differentiation of progenitor cells of the granulocyte-macrophage lineages (Burgess and 
Metcalf, 1980, Metcalf, 1985). Among the CSFs, G-CSF stimulates almost exclusively the 
proliferation and maturation of precursor neutrophilic granulocytes in the bone marrow and 
induces terminal differentiation of certain myeloid leukemia cells (Nomura, et al., 1986, Tamura, 
et al., 1987, Nagata, 1989). Neutrophils play an essential role in defending against bacterial 
infections through inflammatory responses. Injection of recombinant G-CSF (iG-CSF) in 
different species (including Bos taurus) not only elevates peripheral blood neutrophil counts 
(Cullor, et al., 1990a, Cullor, et al., 1990b) but also enhances neutrophil functional activities 
against bacteria, and killing of tumor cells by antibody-mediated cell cytotoxicity (Nagata, 1989, 
Kehrli, et al., 1991). Previous studies have shown that administration of G-CSF to dairy cows 
has resulted in increased resistance to bacterial infection in mammary glands experimentally 
infected with Staphylococcus aureus or Klebsiella pneumonia (Nickerson, et al., 1989, Kehrli et 
al., 1991). It would be useful to have rbG-CSF to evaluate its efficacy as an immune modulator 
against infectious diseases in cattle. For that purpose, we report here the cloning and 
sequencing of bovine G-CSF. 
2. Materials and Methods 
2.1. Cloning strategy 
A cDNA library constructed from bovine endothelial cells in a Uni-Zap XR phagemid vector 
system (Stratagene, LaJolla, CA) was screened using a polymerase chain reaction (PCR)-based 
library enrichment method (Israel, 1993). Primer sequences for G-CSF derived from the ovine 
sequence (Genbank #L07939) were as follows: 5'-AGAGCTTCCTGCTCAAGTGCTTAG-3' 
(forward primer) and 5'-CAGATGTTGGTGGCAAAGTCG-3' (reverse primer). These 
primers amplified a 322 bp fragment that was used as a template to generate a "P-dATP-labeled 
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probe in a thermocycler for plaque hybridization. Plaque lifts and phagemid in vivo excision 
were carried out according to manufacturer's (Stratagene, LaJoila, CA) protocols. A positive 
clone was sequenced in both directions with T3, T7, or sequence-derived oligonucleotides using 
an automated dideoxy chain-termination method (Sanger, et al., 1977) at the Iowa State 
University DNA Sequencing Facility. 
2.2. Leukocyte isolation and activation 
Mononuclear cells (MNC) and neutrophils (PMN) were separated as described (Roth and 
Kaeberle, 1981, Kehrli, et al., 1989). Mononuclear cells were enriched by buoyant-density 
gradient centrifugation on percoll gradients (1.084 sp. gr., 4(X)x for 40 min). Cells were 
harvested and washed in phosphate buffered saline (0.9% NaCl). Mononuclear cells were 
resuspended to 1 x 10® cells/ml in RPMI-1640 medium with 10% fetal bovine serum (Sigma, 
St. Louis, MO) and 50 ^.g/ml gentamicin (Sigma, St. Louis, MO). Cells were stimulated with 
concanavalin A (ConA; 10 ng/ml) (Sigma, St. Louis, MO) for zero, 24, and 48 hours. Total 
RNA was isolated from fi^shly isolated PMN without stimulation or culturing. 
2.3. RNA isolation and RT-PCR for detection of gene expression 
Cells were collected and total RNA isolated using guanidine isothiocynate (TRIzol™, Gibco 
BRL, Gaithersburg, MD) and chloroform, precipitated with isopropanol, and washed with 75% 
ethanol. Total RNA (1 ng) was used in a reverse transcriptase-PCR (RT-PCR) according to the 
manufacturer's protocol (Reverse Transcription System, Promega, Madison, WI). Bovine G-
CSF derived primers for RT-PCRs were as follows: 
5'-AGAGCTTCCTGCTCAAGTGCTTAG-3' (forward primer, nucleotides 147-171) and 
5'-TTCGTGGCAAAGTCAGTGACG-3' (reverse primer, nucleotides 462-443). These 
primers amplified a 316 bp fragment from cDNA and -900 bp from genomic DNA (spans two 
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introns). Expression of bovine glyceraldehyde 3-phosphate dehydrogenase (G3PD), a house 
keeping gene, was used as a positive control in RT-PCR reactions. 
3. Results 
3.1. cDNA encoding bC-CSF 
Using a PCR-based screening method, a full length bC-CSF cDNA was isolated. The 
cDNA sequence consisted of 1465 nucleotides with an open reading frame of 585 bp that 
encodes for 174 amino acids (aa), starting with a methionine codon at nucleotide 53 and ending 
with a termination codon at nucleotide 632 (Figure 1). The signal peptide sequence is 21 aa in 
length which is 9 aa shorter than that of human and murine G-CSF. Comparison of cDNA 
sequence reveals 95%, 89%, 85%, and 76% identity with the ovine, porcine, human, and murine 
G-CSF cDNA respectively (Table 1). This high degree of homology agrees with the 
observations that G-CSF has very little species specificity (Nagata, et al., 1986). Bovine 
G-CSF cDNA contains no consensus sequence for N-glycosylation (Asn-X-Ser/Thr). 
However, like its human counterpart, it might be O-glycosylated at Thr-133 (Kubota, et al., 
1990). The amino acid sequence contains five Cys residues at positions 17, 36,42,64, and 74. 
Cys-17 is a free residue, while Cys-36:Cys-42, and Cys-64:Cys-74 are used for intramolecular 
disulfide linkages. DNA sequence comparison with an existing bovine G-CSF cDNA in 
Genbank (Accession #109541) revealed a four nucleotide difference between the two cDNAs. 
The validity of our sequence difference was confirmed by sequencing genomic DNA from six 
different breeds of cattie (Holstein, Brown Swiss, Jersey, Ayrshire, Milking Short Horn and 
Polled Hereford) including four individual animals firom one breed (Fig. 1 and 2). 
3.2. bG-CSF expression in activated MNC and PMN 
Figure 3A illustrates that freshly isolated neutrophils and mononuclear cells did not express 
G-CSF mRNA based upon RT-PCR analysis. However, 24-48 hour cultures of mononuclear 
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cells stimulated with ConA did express G-CSF mRNA. Unstimulated cultures of mononuclear 
cells at 48 hours also expressed G-CSF mRNA. G3PD mRNA was expressed in all cells 
regardless of stimulation or culture conditions (Figure 3B). 
4. Discussion 
The most unusual feature of bG-CSF cDNA repotted here lies in the 5' region of the 
sequence. Its signal peptide sequence is 21 aa which is 9 aa shorter than those of human 
(Nagata et al., 1986) and murine (Tsuchiya, et al., 1986) G-CSFs, yet equal in length to those of 
rat (Han, et al., 1996) and porcine (Kulmburg, et al., 1997) G-CSFs. The sequence of the 5'-
untranslated region of the ovine G-CSF cDNA has not been reported. A single mutation of 
nucleotide 26 (conversion of a T to an A) in the bovine G-CSF cDNA would have generated the 
exact same translation initiation site, and exact same size of signal peptide sequence as those of 
human and murine G-CSFs. The validity of our cDNA sequence at this region was confirmed 
by sequencing a fragment of genomic DNA (424 bp) spanning the site of discrepancy from 
several different breeds of cattle (Figure 4). The consensus sequence for initiation of 
translation in vertebrates (GCC)GCC'^/QCCATGG (Kozak, 1987), does not exist at the 
translation start codon of the bovine (ATG, nucleotides 53-56, Figure 1), porcine or rat G-CSF 
sequences. This consensus sequence is also not well conserved in human and murine G-CSFs. 
Kozak (Kozak, 1987) speculates that this lack of proper sequence flanking the start codon 
contributes to inefficient in vivo or in vitro expression of hormones and cytokines. Cloning of 
G-CSF in mammalian expression vectors with construction of a consensus sequence for 
initiation of translation at the site of the start codon might lead to high and efficient levels of 
expression (Kulmburg et al., 1997). Finally, sequence analysis shows nearly 100% identity to a 
sequence in GenBank (Accession #109541) with the exception of a discrepancy in a region 
comprising four nucleotides. Deduced amino acid sequence of the region shows that threonine 
and serine are changed to arginine and glycine respectively, in the mentioned GenBaitk 
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sequence. This discordance has been confirmed by sequencing this region of inconsistency in 
our cDNA clone several times, as well as sequencing the corresponding region in genomic 
DNA of six different breeds of cattle, including four unrelated Holsteins and one bison. These 
four nucleotides in the sequence reported here are identical to the corresponding region of ovine 
G-CSF. The existence of multiple alleles of bovine G-CSF is a possible explanation of this 
discrepancy with the other Genbank sequence. Primary monocytes or macrophage cell lines 
(Rambaldi, et al., 1987, Vellenga, et al., 1988), fibroblasts (Zoellner, et al., 1992), endothelial 
cells (Zsebo, et al., 1988), neutrophils (Lindemann, et al., 1989), and bone marrow stromal cells 
(Fibbe, et al., 1988, Kittler, et al., 1992) are all cellular sources of G-CSF. The result of the RT-
PCR analysis revealed that freshly isolated MNC and PMN cells did not express G-CSF. 
ConA stimulated or 48 hour-cultured MNC without ConA stimulation, however, did express 
G-CSF mRNA. Expression of G-CSF by cultured MNC without ConA stimulation is possibly 
due to activation of MNC by culture. Human PMN stimulated with GM-CSF express G-CSF 
mRNA therefore, it is possible that other types of stimuli could induce bovine PMN to express 
G-CSF mRNA. 
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AGAACCTACAGCCCCACCCAGACCCTTGGCTGAGCCTTCTGCCCAGAGCCCC 5 2 
ATG AAG CTG ATG GTC CTG CAG CTG CTC CTC TGG CAC AGT GCG CTC TGG ACG GTG 106 
l f K I . I f V L Q L I . L N B S A . Z . N T V  
CAC GAA GCC ACC CCC CTT GGC CCT GCC CGA TCC CTG CCC CAG AGO TTC CTG CTC 160 
B E A T P X i O P A K S L P Q S r L L  ( 1 5 )  
AAG TGC TTA GAG CAA GTG AGG AAA ATC CAG GCT GAT GGC GCC GAG CTG CAG GAG 214 
K C L B g V R K Z Q A D O A K L Q B  ( 3 3 )  
AGG CTG TGT GCC GCC CAC AAG CTG TGC CAC CCG GAG GAG CTG ATG CTG CTC AGG 268 
R I . C A A H K 1 . C B P B  B L K L L R  ( 5 1 )  
CAC TCT CTG GGC ATC CCC CAG GCT CCC CTA AGC AGC TGC TCC AGC CAG TCC CTG 322 
H S I . a Z P Q A P I . 8 S C S 8 Q 8 I .  ( 6 9 )  
CAG CTG ACG AGC TGC CTG AAC CAA CTA CAC GGC GGC CTC TTT CTC TAC CAG GGC 376 
Q L T S C L M g L B O O L F L Y g O  ( * 7 )  
CTC CTG CAG GCC CTG GCG GGC ATC TCC CCA GAG CTG GCC CCC ACC TTG GAC ACA 430 
I . L Q A Z . A O Z S P B I . A P T L D T  ( 1 0 5 )  
CTG CAG CTG GAC GTC ACT GAC TTT GCC ACG AAC ATC TGG CTG CAG ATG GAG GAC 484 
I . Q I . D V T O P A T M Z  N L Q M E O  ( 1 2 3 )  
CTG GGG GCG GCC CCC GCT GTG CAG CCC ACC CAG GGC GCC ATG CCG ACC TTC ACT 538 
I . O A A P A V 0 P T Q O A H P T P T  ( 1 4 1 )  
TCA GCC TTC CAA CCC AGA GCA GGA GGG GTC CTG GTT GCT TCC CAG CTG CAT CGT 592 
S A F Q R R A O O V L V A S Q L B R  ( 1 5 9 )  
TTC CTG GAG CTG GCA TAC CGT GGC CTG CGC TAC CTT GCT GAG CCC TGA 640 
F L C L A Y R O L R Y L A B P *  ( 1 7 4 )  
GCAC AGCGCTTCCCCTCTCATGTATTTATCTCTGTATTTAATATTTATGCTTATTTAAACCTAATATTTAAAG 713 
AC AGGGAAGCACAGAAAGGAGCCCCAGGCTCCTGGGTCCTTCCTTTCACCTCCATGTGGGGAAAACTCTCCA 786 
CTTGCATACTGGGATTGGG AGGGAGTTGGT AAATACCAAGTATTACTTCTTGTGGCTGCTCCAGGCTTGGCTC 859 
CGCGGTGGGTTCTGGGGAG AGCTGCAGTGAACCCCTACCCTGAGGATGCCCACCTCGGGGCCCTTGGAAGCAT 932 
CGGG AAGTCTCCC AAGTGGGAGATGAGACAGCTCTGTTTAATATTTAAACAGCAGTGTTCCCCAACTGGGTCC 1005 
TTGCCCCCTGGCTCCGGCCCTGCATTCGGGCATGAAGCCCAGCAGAGGCAGCTGGAGTGGGATGCTTGACTCT 1078 
GGGGTCCCACAAATTTGCTGGGGAAACTTCGTCAAGACTTTTTTCAAGCACATTTTGACTCCTCGTGTGGGGA 1151 
GCCCAGGCATCAGTGACGCCTCTTGTTTTTCTGGATGCACTAGAGACGCCATGAGGGTCATGACCTTGCTCCA 1224 
CCCTACCGGGGTTAGGGTCAGGATTCTGACTCTCTTTTGGGCTGGGCAGATGGTCGTATGTCTCTGCCTTGCT 1297 
GGGTGAGACTGGGAAATGGAAAGGAAAGATGAGGGAGCTTGTGTG ACGGGGTGTGAGAGAACACTCAACTGTT 1370 
C ACTTTCCACCCCGGCCCCCACTTTCTCCCTGTAGCCAAACTTCACAATMIMaGTGTTTGTCTCCAGTAAA 1443 
AAAAAAAAAAAAAAAAA 1460 
Figure 1. Nucleotide and deduced amino acid sequences of bG-CSF (Accession No. 
AF092533). Nucleotide numbers are given to the right. Amino acid numbers are within 
parentheses. The putative signal peptide (53-116), the region of discrepancy (329-333), and the 
polyadenylation signal AATAAA (1420-2426) in the 3'-untranslated region are all underlined. 
The termination codon is shown by an asterisk. 
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Table 1 
Comparison of Bos taurus G-CSF to that of other species 
Ovis ovis Sus scrofa Felis Homo Rattus rattus Mus 
domesticus sapiens musculus 
cDNA 95% 90% 86% 86% 82% 79% 
Amino 95% 86% 82% 81% 72% 72% 
Acid 
Percent identities at cDNA and amino acid levels of bG-CSF to those of other species are 
shown. Basic Local Alignment Search Tool (BLAST) was used for these comparisons. 
Figure 2. 
Panel A: Nucleotide sequence encompassing the region of discrepancy with the existing 
GenBank sequence. Nucleotide numbers are given to the right and the amino acid numbers 
are shown within parentheses. Internal primers from sequenced cDNA were used in 
amplification of this fragment. Intron sequences are within parentheses and the conserved 
GT (beginning) and AG (ending) of the introns are underlined. Four underlined nucleotides 
(beginning of exon 4) differ from the corresponding nucleotides in the cDNA sequence 
existing in the GenBank. Deduced amino acid sequence of the region is also shown where 
threonine and serine are changed to arginine and glycine respectively, in the mentioned 
GenBank sequence. Panel B: Nucleotide sequence of the 5' region of bG-CSF gene. 
Nucleotide numbers are given above the sequence and AA numbers are given under the 
corresponding sequence. The 'TATAAA' box (nucleotides -88 to -83) and the signal peptide 
(AA +1 to +21) are underlined. Thr-22 is the start of the mature G-CSF protein. Nucleotide 
-27 (in bold and underlined) is where the signal peptides of human and murine G-CSF start 
(with conversion of the T to an A). Conserved GT of beginning and AG of ending of the first 
intron are underlined. 
A: 
(yt,. . . . qci I (!<|.khkiciI ' I t t.t (|,>t t c|aiKj<i<'ujq(ji)qt t ijiignnycM LyycacjcjacjqgcLt ggggtTcjf) 
ragayat cjt gyayi t y(|.'i(|.i(|c|i i (|y(i()ayga()ciayyaygagyayrt:tgycc:cc't:(;ncf;(;agcaLcc:Lt:cccaccgca 
gf gt yccf|c-cc-af(tau) Clv; C/V: CCii (lAi! liAG CTG A'l'G CTG CTC ACiG CAC TCP CTG GGC A'I'C CCC 
I. <• II I' !•: K 1, M L L R H L G I P 
CAG GC'I' CCtJ ("I'A AGC AC!'' 'l'G(' 'I'CC AGC (.'A(i TCC! CTG (!AG CTG (yt yayt.yLcccaayyggciyaayggagat.ga 
(.) A P I, S S C S S 0 S I, (.) L 
yggqgcgggayyyccigact (lact.M qt aaciyct i.-fcr-aqt t (M et acjyctccaf.'ycagyyaccctiaagciggngcnccccaggtggcgL 
c:c;ccM yacM cM ccc.iccl .i.u'fcccray) Ai.M.i Ai;(,' TGC CTG AAC CAA CTA ("AC GGC GGC C'l'C TTT CTC TAC 
T S C I, N 0 !, II G G I, F I, Y 
CA(; GlSC CTC C'I'G CAG GCC C'l'G GC(.; GGC A'I'C TCC CCA GAG CTG GCC CCC ACC TTG GAC ACA CTG CAG 
0 G I, I, (.) A 1, A G I P K A P T T I, I) T I, 0 
B; 
180 K.tl -HO -I'^.O -100 
CTCACTCTGACAACAAATTTGCATAAAACTTc^iiGAAGCTATTACTAAGCCiTTAGTCGCAGCACCAGGTAATTTCCTCCCAGACCTCCA 
HO -f)0 --lO •?.() 
TGC;GC'rTGAATATAAAGGCCCCA(:!(;A(;CTGi;TCCCTGACAGAACCCAGAACCTACA(X:CCCACCCAGACCCTTGGCTGAGCCTTCTGC 
1 ;;o -10 60 
CCAGAGt.'CCC ATG AA(,! (,")'G A^l'G G (yI()agLgtcLggytcclgggayggyagagct:gcggcagcagcgggcagyggtgcctgg 
M K 1, M 
1 
00 1(10 no MO 
yetLccaLaaa()(ji ct (jt-acM t tM.cct.yagcccccat.cl gcM ctcay) TC CTG CAP CTG CTC CTC TGG CAC AGT_ UCG 
V 1, 0 1, i, 1, W II S A 
10 
1611 lf!0 200 
CTC TGG ACG GTG CAi.' C.AA GCC ACC CCC CTT GGC CCT GCC CGA TCC CTG CCC CAG AGC TTC CTG CTC 
L W T V II I'. A T P 1, G P A U G L P 0 S F L L 
.111 .;] 30 
80 
167 
234 (57) 
306 
(31) 
393 
463 (IS) 
529 (67) 
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A. 
I 2 3 4 5 6 7 
(;3PI) 
Figure 3. Agarose gel electrophoresis of RT-PCR results. Panel A (bG-CSF expression): 
(lanel) 100 bp ladder, (lanes 2, 3.4) 0. 24,48 h ConA stimulated culture of MNC, (lane 5) 48 h 
culture of MNC without ConA stimulation, (lane 6) PMN, (lane 7) PGR positive control 
(Plasmid with G-CSF cDNA). Panel B (G3PD expression): (lane 1) 100 bp ladder, (lanes 2-
6) correspond to lanes 2-6 in panel A. (lane 7). negative control (Reaction of the lane #2 without 
reverse transcriptase). 
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EXPRESSION, PURIFICATION, AND IN VITRO 
BIOLOGICAL ACTIVITIES OF RECOMBINANT BOVINE 
GRANULOCYTE COLONY STIMULATING FACTOR 
A paper to be submitted to Veterinary Immunology and Immunopathology 
Mohammad Heidari, James A. Harp, Marcus E. Kehrli, Jr. 
Abstract 
Neutrophils are essential components of the innate immune system and they play a critical 
role in the host's defense against bacterial and fungal infections. The colony stimulating 
factors are a class of glycoproteins that are required for proliferation, differentiation, and 
functional activation of hematopoietic progenitor cells. Granulocyte colony stimulating factor 
(G-CSF) is a member of this regulatory family of cytokines that specifically stimulates 
proliferation and maturation of precursor cells in the bone marrow into fully differentiated and 
functional neutrophils. G-CSF also modulates the biological activities of mature neutrophils in 
circulation. A bovine G-CSF (bG-CSF) cDNA clone (previously isolated and sequenced in our 
laboratory) was expressed in E. coli and the biological activities of the solubilized protein from 
purified inclusion bodies were examined. Flow cytometric analysis of membrane antigen 
density of neutrophils activated with bG-CSF revealed an upregulation in the expression of 
CDI la (>110%), CDllb (>144%), CDllc (> 85%), andCDlS (> 110%). Expression of 
L-selectin was decreased by more than 44%. There was no change, however, in the expression 
of CD 14. These findings indicate that recombinant bG-CSF (rbG-CSF) expressed in E. coli is 
biologically active and exerts the same type of effects on neutrophils in vitro as those of human 
G-CSF (hG-CSF). 
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1. Introduction 
Colony stimulating factors are a group of regulatory hematopoietic cytokines that are 
essential for survival, proliferation, and differentiation of bone marrow progenitor cells (Burgess 
and Metcalf, 1980, Metcalf, 1985). G-CSF preferentially promotes proliferation and 
differentiation of progenitors of polymorphonuclear leukocytes and induces terminal 
differentiation of some myeloid leukemia cells (Fujisawa, et al., 1986, Nomura, et al., 1986, 
Tamura, et al., 1987, Nagata, 1989). In addition to its effect on hematopoiesis, G-CSF also 
enhances neutrophil functions against bacteria, fungi, and tumor cells mediated by antibody-
dependent cell-mediated cytotoxicity (Nagata, 1989, Kehrli, et al., 1991, Roilides, et al., 1991, 
Roilides, et al., 1993, Valerius, et al., 1993). In vivo and in vitro studies have shown that 
activation of neutrophils by hO-CSF enhances superoxide (O, ) release (Kitagawa, et al., 1987, 
Yuo, et al., 1989, Avalos, et al., 1990), increases expression of CDl lb (a subunit of Mac 1) 
(Kitagawa, et al., 1987, Yong and Linch, 1992, Hansen, et al., 1993), CD 18 (P subunit of P2 
integrin) (Liles, 1994, Carulli, et al., 1997, Inano, et al., 1998, Zhang, et al., 1998) and decreases 
the expression of L-selectin (Yong and Linch, 1992, Ohsaka, et al., 1993, Liles, ET AL., 1994, 
Turzanski, et al., 1997) which leads to an increase in serum concentration of soluble selectins 
(Ohsaka, et al., 1998). In vivo administration of hC-CSF also increases surface expression of 
Sialyl-Lewis" and interleukin-8 receptors on polymorphonuclear leukocytes (Lloyd, et al., 1995, 
Ohsaka and Saionji, 1998). There are also some indications that activation of neutrophils by 
G-CSF induces an increase in affinity binding of L-selectin to its ligands on endothelial cells 
(Spertini, et al., 1991). This enhanced receptor affinity is predicted to be due to conformational 
changes in the receptor binding site(s) of L-selectin. All these modulatory effects of G-CSF on 
neutrophils are critical for adhesive interactions of phagocytes with endothelium and their 
eventual recruitment and accumulation at the site of infection (Amaout, 1990b, Springer, 1990). 
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Most of the studies concerning biological activities of G-CSF were done on human 
recombinant G-CSF. Very few in vivo and almost no in vitro studies have been reported on 
bG-CSF. For this reason, we expressed rbG-CSF in E. coli and have functionally active protein 
from inclusion bodies. Our data show that bG-CSF induces upregulation of CDl la, CDl lb, 
Cdl Ic, CD 18 and proteolytic cleavage of L-selectin upon activation of neutrophils for 30 min at 
39 °C. These observations are both time and concentration dependent. 
2. Materials and Methods 
2.1. Construction of the plasmid 
Bovine G-CSF cDNA was previously cloned and sequenced in our laboratory (Heidari and 
Kehrli, 2000). The complete coding sequence of bG-CSF was amplified by polymerase chain 
reaction using pBluescript-bGCSF as a template ((Heidari and Kehrli, 2000). Primer 
sequences for amplification of this DNA fragment were as follows: 
5' -AATATGGATCCACCCCCCTTGGCCCTGCC-3' (forward primer) and 
5' -CAGGCGGTACCTCAGGCCTCAGCAAGGTA-3' (reverse primer). The underlined 
nucleotides are 5' extensions which contain BamHl (GGATCC), and Kpnl (GGTACC) sites 
for subcloning of the amplified fragment into the expression vector. Expression vector used 
was pQE30 (Qiagen, Valencia, CA) which contains a unique N-terminal 6-residue His-tag. 
Sequence analysis of the construct confirmed that the cloned cDNA was in frame with the His-
tag and initiation codon (ATG). 
2.2. Expression of bG-CSF 
Escherichia coli strain M15 (Qiagen) was transformed by the pQE30-bGCSF construct and 
which confers resistance to kanamycin and expresses high levels of Lac repressor protein 
encoded by the Lac I gene. This unique feature of the expression system tightly regulates 
recombinant protein expression until addition of isopropyl-P-D-thiogalactoside (IPTG) which 
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positive transformants were selected on Luria-Bertani plates containing 100 |Ag/ml ampicillin 
and 25 ng/ml kanamycin. This strain of E. coli contains the low-copy plasmid, pREP4, 
inactivates the repressor protein and consequently leads to the expression of the recombinant 
protein. For expression, an overnight culture of E. coli (M15) containing pQE30-bGCSF was 
diluted 100 fold with Super Broth (32 g tryptone, 20 g yeast extract, 5g NaCl, 5 ml 1 N NaOH 
per liter) containing antibiotics (ampicilin and kanamycin) and incubated at 37°C with vigorous 
shaking until an ODj^o = 0.5 was reached. Expression was induced by addition of IPTG (1.0 
mM final concentration) and cells were incubated at 37°C for a further 3 h before collecting by 
centrifugation. The cell pellet was kept at -20°C for later use. 
2.3. Purification of inclusion bodies 
Small-scale expression revealed that bG-CSF was produced in the form of an insoluble 
protein (inclusion bodies) and further folding and oxidation was required for solubilization and 
functional activities of the protein (Figure 1). Cell pellets were resuspended in lysing buffer 
(100 mM KCl; 25 mM HEPES, pH 7.6; 0.1 mM EDTA, pH 8; 12.5 mM MgCl,; 10% 
glycerol; 0.1% Triton X-100) containing 0.5 mg/ml lysozyme and incubated on ice for 1 h. 
Suspension was sonicated (Sonicator W-375, Heat Systems-Ultrasonics, Farmingdale, NY) by 
short-wave pulses of 30 sec followed by cooling until the solution was clear. The inclusion 
bodies were collected by centrifugation at 30,000 g for 30 min at 4°C. The pellet was washed 
several times with PBS containing 0.1% Triton X-100 to remove native soluble proteins. 
2.4. Solubilization and oxidation 
Solubilization and oxidation of bG-CSF was carried out according to a published protocol 
for hO-CSF with minor modifications (Lu, et al., 1992). Inclusion bodies, that were relatively 
free of contamination at this stage, were solubilized in 2% sarkosyl, 50 mM Tris-HCl, pH 8 for 
30 min at 25°C. The final protein concentration was 0.5 ng/ml. CuSO^ was added to a final 
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concentration of 40 joM and the solution was stirred for 24 h at 25°C. The solution was 
centrifuged at 30,000 g for 30 min to remove insoluble debris and was dialyzed against distilled 
water several times to remove sarkosyl and finally against His-tagged protein purification 
column buffer (50 mM NaHjPO^, pH 8.0; 300 mM NaCl; 10 mM imidazole) (Qiagen). 
Column purification of the soluble protein was done according to the manufacturer's protocol 
(Qiagen). The column eluted purified protein was finally dialyzed against PBS and the 
concentration was determined by Pierce Micro BCA Protein Assay Reagent (Pierce, Rockford, 
IL). 
2.5. Monoclonal antibodies 
Monoclonal antibodies (mAb) were from Veterinary Medical Research Diagnostics, 
Pullam,WA. Table 1 shows the isotypes and the working concentrations of all the mAbs used. 
The secondary antibodies were FITC-conjugated sheep anti-mouse IgG (F(ab')2) (Sigma, 
St. Louis, MO), and goat anti-mouse IgM (F(ab')2) (Southern Biotechnology, Birmingham, 
AL). An FITC-conjugated monoclonal mouse IgGl (Specific fox Aspergillus niger glucose 
oxidase) was used as a negative control (DAKO, Denmark). 
2.6. Activation of neutrophils 
Whole blood obtained from three young Jersey calves (< 3 months old) was used for the 
analysis. Fifty-microliter aliquots of whole blood were added to each of seven wells in a 
microtiter plate for each calf. The first well of each sample received 50 ^ 1 PBS (negative 
isotype control) and the next three wells also received 50 PBS (non-stimulated control). 
The remaining three wells received 50 fil PBS + bG-CSF (100 ng/well). Samples were gently 
mixed and incubated at 39°C for 30 min. After incubation, 10 |il of primary monoclonal 
antibody to the appropriate surface molecule was added to all wells except the isotype control 
well. Samples were gently mixed again and incubated at 4°C for 30 min. The plate was 
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centrifuged at 800 g for 2 min at 4°C. Supematants were removed and erythrocytes were lysed 
with 150 (il of hypotonic solution (Burton, et al., 1995) for 1 min. Then 75 ^i of hypertonic 
restoring solution was added to restore the isotonicity (Burton et al., 1995). The lysing process 
was repeated once more and the cells were washed once with 200 ^ 1 PBS. Finally cells were 
resuspended in 150 jil of PBS and 10 ^1 of negative isotype control was added to the first well 
and 10 (J.1 of secondary antibody to the remaining six wells. Samples were incubated at 4°C for 
20 min. The plate was centrifuged, supernatant decanted, and cells were resuspended in 200 ^ 1 
of sheath fluid (Isoton 11; Coulter Diagnostics, Hialeah, FL) for flow cytometric analysis. 
2.7. Flow cytometric analysis 
The expression of surface antigens on neutrophils was determined by using a FACScan™ 
flow cytometer (Becton Dickinson, San Jose, CA). Data obtained from 4,000 selectively gated 
neutrophils based on their forward and side scatter properties was analyzed by CellQuest™ 
software (Becton Dickinson). The mean fluorescent intensity was determined by comparing the 
fluorescence intensity of the test antibodies with that of isotype control stained cells. 
3. Results 
3.1. Expression and purification of bG-CSF 
Figure 1 shows the result of bG-CSF expression in E. coli. As the Commassie brilliant 
blue-stained precast SDS-polyacrylamide gel (Novax, San Diego, CA) reveals, there is no 
expression of recombinant bG-CSF peinduction (lane 1). Upon IPTG induction of expression, 
a band migrating at a molecular size of approximately 20.5 KD appears 1 h post induction (lane 
2) and increases in intensity after 2 and 3 h post induction incubation (lanes 3 and 4, 
respectively). Solubilized and colunm purified bG-CSF is depicted in lane 5. Eleven amino 
acid residues added to the N-terminal of bG-CSF in the process of cloning into pQE30 
(including the 6 x His-tag) were not removed after purification and apparently did not affect the 
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functional activities of bG-CSF. As mentioned before, bG-CSF is produced as an insoluble 
protein and is present only in the insoluble fractions of the cell lysates. The soluble fractions 
are not shown. 
3.2. Flow cytometric analysis 
Representative fluorescence histograms of gated neutrophils are shown in Figures 2,3,4,5, 
6, and 7. Marker Ml denotes the area of positive fluorescence and M2 the area of the 
background fluorescence. The optimal concentration of rbG-CSF for these effects was 2 ^g/ml 
at 39°C incubation for 30 min. 
3.3. Effect of rbG-CSF on expression of CDl lb 
Figure 2C shows that the geometric mean fluorescence values of CDl lb increased from 
51.39 to 127.45 (>144%) when neutrophils were activated by rbG-CSF. Incubation of 
neutrophils with PBS alone at 39°C did not increase the fluorescence intensity (Fig. 2B) in 
comparison to cells incubated with PBS at 4°C (Fig. 2A). Figure 2D represents histogram of 
isotype control antibody staining of cells. 
3.4. Effects of rbG-CSF on expression of CD 18 
Figure 3C shows that geometric mean fluorescence values of CD 18 were increased from 105 
to 220 (>110%) upon activation of neutrophils by rbG-CSF. Figures 3A and 3B represent 
fluorescence intensity of CD 18 on neutrophils incubated with PBS at 4°C or 39°C, 
respectively. Figure 3D is shows the histogram of cells stained with isotype control antibody. 
3.5. Effect of rbG-CSF on expression of L-selectin 
Figure 4C shows that unlike, CDl lb and CD18, the mean fluorescence intensity of 
L-selectin was decreased by more than 44% after neutrophil treatment with rbG-CSF 
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(geometric mean: 94.75 to 53.15). Figures 4A and 4B represent fluorescence intensity of 
L-selectin after incubation of cells with PBS at 4°C and 39°C, respectively. Figure 4D shows 
the histogram of cells stained with isotype control antibody. 
3.6. Effect of rbG-CSF on the expression of CDl la 
Expression of CDl la was also upregulated by more than 110% (geometric mean: 92.28 to 
197.81; Figure 5C). This finding is in contrast to the observation that human neutrophils do 
not store preformed CDl la and its expression remains unchanged upon short-term in vitro 
activation by G-CSF. Figures 5A and 5B represent the expression level of CDl la on non-
stimulated neutrophils incubated at 4°C and 39°C, respectively. Figure 5D represents the 
histogram of cells stained with isotype control antibody. 
3.7. Effect of rbG-CSF on the expression of CDl Ic 
Figure 6C shows that there was an 85% increase in the fluorescence intensity of CDl Ic on 
the activated neutrophils (geometric mean values: 5.71 to 10.68). Expression levels of CDllc 
on non-activated PMN incubated at 4°C and 39°C are shown by Figures 6A and 6B, 
respectively. Figure 6D represents the isotype control staining of the cells. 
3.7. Effects of rbG-CSF on the expression of CD 14 
Expression of CD 14, receptor for LPS, was unaffected by rbG-CSF treatment of neutrophils 
(Figure 7). Geometric means of the expression level, as well as the histograms, reveal that 
CD 14 is expressed at very low levels and it is not upregulated upon 30 min activation of 
neutrophils with G-CSF. 
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4. Discussion 
Neutrophil-mediated immune response is a critical component of the innate immune 
mechanism against bacterial and fungal infections (Gabay, 1988, Etzioni and Douglas, 1993). 
A successful transendothelial migration of neutrophils into the area of inflammation in response 
to various chemoattractants is a requirement for the fulfillment of this essential role of these 
phagocytic cells (Etzioni and Douglas, 1993, Adams and Shaw, 1994). 
The adhesive interaction between neutrophils and endothelial cells is dynamic and a multistep 
process (Springer, 1990, Butcher, 1991, Springer, 1994). The initial step of neutrophil 
extravasation is mediated by the selectin family of adhesion molecules (Kishimoto, 1991, Varki, 
1994). This transient and reversible interaction can trigger an upregulation in the expression of 
a second family of adhesion molecules, the p2-integrins, that mediate tight binding and arrest of 
neutrophils on endothelial cells for subsequent tissue migration (Price, et al., 1987, Hynes, 
1992). 
The central importance of these adhesion molecules mediating the interaction between 
neutrophils and vascular endothelial cells is more apparent in leukocyte adhesion deficiency 
syndrome (LAD-I) of humans, dogs, and cattle, characterized by life threatening recurrent 
bacterial and fungal infections and severe reduction of the accumulation of neutrophils at sites 
of inflammation (Renshaw and Davis, 1979, Anderson and Springer, 1987, Amaout, 1990a, 
Kehrli, et al., 1990). This disorder is caused by mutations in the common P subunit of ^2 
integrins that leads to low or complete lack of expression of all heterodimeric members of this 
family of adhesion molecules (Amaout, et al., 1990). 
Another form of leukocyte adhesion deficiency has been described (LAD-II) where 
neutrophils lack the expression of Sialyl-Lewis*, a ligand for E, P, and L-selectins (Etzioni, et 
al., 1992). Lack of expression of these adhesion molecules results in recurrent pneumonia, 
bacterial infection, and persistent leukocytosis, all of which underline the importance of adhesive 
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interaction between neutrophils and endothelial cells mediated by these surface antigens (Etzioni 
et al., 1992, Etzioni and Douglas, 1993). 
G-CSF is a member of the hematopoietic colony stimulating factors that is primarily 
produced by monocytes-macrophages (Sallerfors and Olofsson, 1992), fibroblasts (Zoellner, et 
al., 1992), bone marrow stromal cells (Thalmeier, et al., 1996), and endothelial cells (Zsebo, et 
al., 1988). High level expression of G-CSF is induced by interleukin-l, a proinflaimnatory 
cytokine, in the course of bacterial infection or lipopolysaccharide-stimulated immune 
responses (Furuya, et al., 1993, Shirai, et al., 1997). Previous studies have shown that G-CSF 
induces recruitment of mature and fxinctionally active neutrophils from bone marrow (Burgess 
and Metcalf, 1980, Metcalf, 1985), shortens neutropenia in chemotherapy patients (Boxer, et al., 
1992), and increases bactericidal and fungicidal activities of mature neutrophils (Roilides et al., 
1991, Roilides et al., 1993). 
Recent observations indicate that G-CSF may provide additional protective effects by 
induction of Th2 type of cytokines, as well as IL-1 receptor antagonist, and tumor necrosis 
factor receptor, altering the balance of cytokine synthesis from a proinflammatory to an 
antiinflammatory response (Dale, 1994, Hartung, et al., 1995, Hannen, et al., 1999). 
Effects of G-CSF on adhesion molecule-dependent activities of neutrophils in vivo and in vitro 
have also been extensively studied. G-CSF has been shown to increase CDl lb/CD 18 (Mad) 
expression on neuU-ophils (Kitagawa et al., 1987, Yuo et al., 1989, Avalos et al., 1990, Yong and 
Linch, 1992), and to enhance L-selectin affinity binding (Spertini et al., 1991) before promoting 
its shedding that is a prerequisite for P2-integrin-mediated tight adhesion (Yong and Linch, 
1992, Ohsaka et al., 1993, Liles et al., 1994, Turzanski et al., 1997). In vivo administration of 
rhG-CSF increases the expression of CD 14 (LPS receptor) as well as the Fc receptor for IgG 
(FcRl, CD64) (Hansen et al., 1993, Ohsaka, and Saionji, 1998). It also enhances chemotactic 
(Wang, et al., 1988), phagocytic (Ogle, et al., 1990, Roilides et al., 1991), and bactericidal and 
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fungicidal activities of neutrophils in vitro (Roilides et al., 1991, Roilides et al., 1993). G-CSF 
also prolongs survival and delays apoptosis of neutrophils (Balazovich, et al., 1991). 
Our in vitro studies with rbG-CSF confirm some of the previous findings with rhG-CSF. 
Short term activation of neutrophils with rbG-CSF induces an upregulation of expression of 
CDlIa (a subunit of LFA-1), CDl lb (a subunit of Mac 1), CDl Ic (a subunit of pl50,95), 
and CD 18 (the common P subunit of P2 integrins). This upregulation is not the result of a 
de novo synthesis of ^2 integrins, but rather due to a rapid recmitment of presynthesized 
adhesion molecules within the secondary intracellular granules. Both CDllb/CD18 and 
CDlic/CDlS are stored preformed in secretary vesicles and are mobilized to the surface of 
activated neutrophils (Springer, et al., 1984, Todd, et al., 1984, Miller, et al., 1987). The unique 
observation that CDl la expression on activated bovine neutrophils was highly upregulated, is in 
direct contrast to the findings that CDl la is not stored presynthesised and its expression 
remains unchanged on human neutrophils activated under similar conditions. This upregulation 
of CDl la expression was also observed on bovine neutrophils activated by platelet activating 
factor (data not shown). This discrepancy can be explained in two possible ways. 1) At least in 
bovine, CDl la, like CDl lb and CDl Ic, is preformed and stored within secondary granules and 
is rapidly recruited to the surface of the activated neutophils. 2) Anti-CDl la mAb used in our 
studies, was reacting against a different adhesion molecule (e.g., CDl lb, CD 18). There is no 
evidence, however, to support the latter. L-selectin expression was down regulated as it is 
expressed constitutively on resting neutrophils and is shed in response to chemoattractants 
(Spertini et al., 1991, Kuijpers, et al., 1992, Liles et al., 1994). CD14, a myelomonocytic 
differentiation antigen, is expressed at high levels on monocyte-macrophages and at very low 
level on neutrophils (Hansen et al., 1993). This bacterial LPS receptor is not stored 
presynthesized within granules and its expression level remains unchanged upon short term in 
vitro neutrophil activation of human neutrophils (Hansen et al., 1993, Liles et al., 1994). Our 
data support these findings. 
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In conclusion, the development of recombinant bG-CSF, like its human counterpart, will most 
likely have a major influence on the prevention and treatment of many diseases. Experimental 
infections with animal models, pre- or post treated with G-CSF, have consistently proven the 
critical importance of G-CSF in host defense augmentation by reducing the occurrence of fever 
and infections. Results obtained from our studies indicate that bG-CSF may play a critical role 
in the inflammatory process by modulating the expression of adhesion molecules and other 
surface glycoproteins essential for the functional activities of neutrophils. 
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Table 1. Monoclonal antibodies used to assess neutrophil adhesion molecule expression. 
Antibody Ig Isotype Concentration Cell line 
CD 11a IgG. 21 ^g/ml BAT75A 
CDIlb IgG. 10 (xg/ml MM12A 
CD 11c IgM 14 M'g/m] BAQ153A 
CD18 IgG. 12 ^g/ml BAQ30A 
CD62L IgG. 14 Hg/ml BAQ92A 
CD 14 IgG, 21 Hg/ml MM61A 
* Antibodies from Veterinary Medical Research Diagnostics, Pullman, WA 
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Figure 1. Expression of bG-CSF. E. coli -produced protein was analyzed under denaturing 
condition on a Commassie brilliant blue stained SDS-polyacrylamide gel. Lane M: Molecular 
weight standards; Lane 1: preinduction insoluble lysate fraction; Lanes 2, 3, and 4: 1,2, and 3 h 
postinduction insoluble fractions, respectively; Lane 5: solubilized and column purified bG-
CSF. 
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Figure 2. Expression of CDl lb on bovine neutrophils in whole blood. Aliquots of whole 
blood were incubated with PBS at 4°C (A), at 39°C (B), or with PBS + rbG-CSF (2n^ml) at 
39°C for 30 min (C). Panel D shows the fluorescence intensity of isotype control antibody 
staining of the cells. 
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Figure 3. Expression of CD18 on bovine neutrophils in whole blood. Aliquots of whole blood 
were incubated with PBS at 4°C (A), incubated with PBS at 39°C for 30 min (B), or with PBS 
+ rbG-CSF (2ng/ml) at 39°C for 30 min (C). Panel D shows the fluorescence intensity of 
isotype control antibody staining of the cells. 
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Figure 4. Expression of L-selectin on bovine neutrophils in whole blood. Aliquots of whole 
blood were incubated with PBS at 4°C (A), at 39°C for 30 min (B), or with PBS + rbG-CSF 
(2ng/ml) at 39°C for 30 min (C). Panel D represents histogram of cells stained with isotype 
control antibody. 
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Figure 5. Expression of CDl la on bovine neutrophils in whole blood. Aliquots of whole 
blood were incubated with PBS at 4°C (A), at 39°C (B), or with PBS + rbG-CSF (2n^ml) at 
39°C for 30 min (C). Panel D shows the fluorescence intensity of isotype control antibody 
staining of the cells. 
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Figure 6. Expression of CDl Ic on bovine neutrophils in whole blood. Aliquots of whole 
blood were incubated with PBS at 4°C (A), at 39°C (B), or with PBS + rbG-CSF (2|j,^ml) at 
39°C for 30 min (C). Panel D shows the fluorescence intensity of isotype control antibody 
staining of the cells. 
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Figure 7. Expression of CD14 on bovine neutrophils in whole blood. Aliquots of whole blood 
were incubated with PBS at 4°C (A), at 39°C (B), or with PBS + rbG-CSF (2(i.^ml) at 39°C 
for 30 min (C). Panel D shows the fluorescence intensity of isotype control antibody staining 
of the cells. 
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GENERAL CONCLUSIONS 
Polymorphonuclear granulocytes (PMN. neutrophils) are the critical component of the 
nonspecific immune system that play an essential role in recognizing and destroying micro­
organisms that enter the body. The importance of these phagocytic cells in host defense is 
more apparent in neutropenia and deflciencies in functional activities of neutrophils where 
humans and animals are predisposed to life threatening fungal and bacterial infections 
(Renshaw and Davis, 1979, Anderson and Springer, 1987, Amaout, 1990, Amaout, et al., 1990, 
Kehrli, et al., 1990, Etzioni, et al., 1992). The defense strategy of this part of the innate immune 
system is coordinated and regulated through signal transduction induced by cytokines and lipid 
mediators. Hematopoietic growth factors are regulatory molecules that are required for survival, 
clonal proliferation, and differentation of blood cells (Burgess and Metcalf, 1980, Metcalf, 
1985). Granulocyte-colony stimulating factor (G-CSF) is a member of this family of cytokines 
that appears to play a vital role in the formation, and maturation of precursur myeloid cells in the 
bone marrow into fully differentated neutrophils. G-CSF also modulates various aspects of 
functional activities of mature neutrophils in response to infectious diseases (Nagata, et al., 
1986b, Nomura, et al., 1986, Tamura, et al., 1987). 
The objectives of this study were: (1) to clone, sequence, and characterize the cDNA 
encoding bovine G-CSF (bG-CSF); (2) to express the cloned bG-CSG cDNA in Escherichia 
coli, purify, and examine the biological activities of the solubilized protein in vitro. 
In the first experiment, we isolated and sequenced a full-length cDNA clone encoding bG-
CSF from an endothelial cell cDNA library, using a polymerase chain reaction-library 
enrichment method (Israel, 1993). The cDNA is 1460 nucleotides in length, with 585 
nucleotides comprising an open reading frame that encodes for 174 amino acids. The signal 
peptide of the mature protein is 21 amino acids long, which is 9 amino acids shorter than that of 
human and murine G-CSG (Nagata, et al., 1986a, Tsuchiya, et al., 1986), but similar to that of 
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rat and porcine G-CSF (Han, et al., 1996, Kuimburg, et al., 1997). G-CSF is highly conserved 
through the evolution of species and sequence analysis reveals that bG-CSG has 95,89, 85, and 
76 % identity with ovine, porcine, human, and murine G-CSF cDNA , respectively. Like its 
human counterpart, bG-CSF contains no consensus sequence for N-glycosylation and may be 
O-glycosylated at Thr-133 (Kubota, et al., 1990). The amino acid sequence contains five Cys 
residues, four being used in the formation of intramolecular disulfide bonds and one free, 
partially solvent-exposed, residue at position 17 (Ishikawa, et al., 1992, Arakawa, et al., 1993). 
In the second experiment, we expressed the bG-CSF cDNA in a prokaryotic expression 
system and studied the biological activities of the purified and solubilized protein on bovine 
PMN in vitro. The expressed bG-CSF was insoluble (inclusion bodies) and had to be oxidized 
and refolded in order to obtain a biologically active protein (Lu, et al., 1992). Our in vitro 
studies showed that activation of bovine neutrophils with recombinant bG-CSF (rbG-CSF) for 
30 min at 39° C (2|ig/ml) increased the expression levels of adhesion molecules CDl la 
(>110%), CDl lb (>144%), and CDl Ic (>85%). L-selectin expression was down regulated by 
more than 44% and CD 14 (the receptor for bacterial lipopolysaccharide) remained unchanged. 
In human neutrophils, CDl lb/CD 18 (Mac-1, 6, integrin) and CDl lc/CD18 (pi50. 95, B, 
integrin ) are known to be presynthesized and stored within secondary granules and rapidly 
recruited to the surface of cells upon short term activation with G-CSF (Springer, et al., 1984, 
Todd, et al., 1984, Miller, et al., 1987). CDlla/CD18 (LFA-1, B, integrin) expression, however, 
remains unchanged. The observation that the expression of CDl la was also upregulated on 
rbG-CSF-activated bovine PMN suggests that the regulation of this member of the Bj integrins 
could be species specific and in bovine neutrophils, CDl la is preformed and stored within 
secondary cytoplasmic grancules before its mobilization to the surface of activated neutrophils. 
CD 14 expression was not increased, similar to results in other species, as it is not preformed 
and stored prior to activation (Hansen, et al., 1993). 
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L-selectin has been shown to be constitutively expressed on resting PMN and it is 
proteolytically cleaved in response to chemoattractants (Spertini, et al., 1991, Kuijpers, et al., 
1992, Liles, 1994). Thus, in the present study L-seiectin was down regulated upon activation 
with rbG-CSF. 
In summary, data obtained from this study reveals that our cloned rbG-CSF is biologically 
active and exerts similar effects on bovine neutrophils as its human counterpart investigated 
previously. 
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APPENDIX A 
CLONING AND SEQUENCING OF cDNA ENCODING BOVINE 
INTERLEUKIN-7 
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Cloning and sequencing of cDNA encoding bovine interleiikin-T 
Introduction 
Interleukin-7 (IL-7) is a growth factor that was first characterized as having proliferative 
effects on B cell precursors in vitro (Namen, et al., 1988). Subsequently, it was shown to be a 
critical cytokine in the regulation of T lymphocyte development (Conlon, et al., 1989). In vivo 
administration of recombinant IL-7 into normal adult mice increases peripheral T cells 
(Morrissey, et al., 1991b, Komschlies, et al., 1994) and enhances recovery of T cells in 
irradiated or chemotherapy treated mice (Morrissey, et al., 1991a, Faltynek, et al., 1992). 
Increase in peripheral blood T cells have also been demonstrated in IL-7 transgenic mice 
(Samaridis, et al., 1991). It has also been shown that IL-7 enhances the generation of cytotoxic 
T lymphocytes and lymphokine-activated killer cells (Alderson, et al., 1990, Hickman, et al., 
1990). In vivo studies have further indicated that administration of neutralizing antibodies to 
IL-7 or IL-7 receptor inhibits both B and T cells lymphopoiesis (Grabstein, et al., 1993, Sudo, et 
al., 1993). These findings suggest a potential avenue for the clinical development of IL-7 as an 
immunomodulator for the prevention or treatment of infectious diseases. We report here the 
cloning and sequencing of a full-length cDNA encoding bovine IL-7 (bIL-7) from an 
endothelial cell cDNA library. 
Material and Methods 
A cDNA library constructed from bovine endothelial cells in a Uni-Zap XR phagemid vector 
system (Stratagene, LaJolla, CA) was screened using a polymerase chain reaction (PCR)-based 
library enrichment method (Israel, 1993). Primer sequences for IL-7 derived from the ovine 
sequence (Genbank #U10089) were as follows: 5' -TCCTCCCCTGATCCTTG11C1G-3' 
(forward primer) and 5'-GTGGTTTTCTTCCTTTACCCTrGC-3' (reverse primer). 
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These primers amplified a 341 bp fragment that was used as a template in a thermocycler to 
generate a ^^P-dATP-labeled probe for plaque hybridization. Plaque lifts and phagemid in vivo 
excision were carried out according to manufacturer's (Stratagene, LaJolla, CA) protocols. A 
positive clone was sequenced in both directions with T3, T7, or sequence-derived 
oligonucleotides using an automated dideoxy chain-termination method (Sanger, et al., 1977) at 
the Iowa State University DNA Sequencing Facility. 
Results and Discussions 
Using a PCR-based screening method, a full-length cDNA encoding bIL-7 was isolated. 
The cDNA sequence consist of 1564 nucleotides with an open reading frame of 531 bp that 
encodes for 176 amino acids, starting with a methionine codon at nucleotide 85 and ending with 
a termination codon at nucleotide 529 (Fig. 1). IL-7 has been relatively conserved through the 
evolution of mammalian species both at the nucleotide and amino acid levels. This observation 
is confirmed by the fact that human IL-7 has little or no species specificity indicating 
conservation of tertiary stmcture or receptor binding domain in addition to its primary sequence 
(Barcham, et al., 1995). Comparison of cDNA sequence reveals 97,91, 83, and 82% identity 
with ovine, porcine, human, and murine IL-7 cDNA, respectively. Bovine IL-7 contains three 
consensus sequences for N-glycosylation (Asn-X-Ser/Thr) and six Cys residues that are likely 
used for intramolecular disulfide bridges. The signal peptide of bIL-7 is 25 amino acid long 
(Fig. !)• 
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AGGGTCCTGGGAGTGACTATGGGCGGTGAGAGCGTGCTCCTGCTGCAGTTGCGGTCATCA 60 
TGACCACGCCCGCTCCCGCAGACCATGTTCCATGTTTCTTTTAGGTATATCTTTGGA-ATT 120 
M F H V S F B X I E Q I (12) 
CCTCCCCTGATCCTTGTTCTGTTGCCAGTAGCATCATCTGATTGTGATATTAGCGGTAAA 180 
P P L T T . V L L P V A S S  D C D I S G K (32) 
GACGGTGGAGCATATCAGAATGTTCTAATGGTCAACATCGATGACTTGGACAACATGATA 240 
D G G A Y Q N V L M V N I  D D L D N M I  ( 5 2 )  
AACTTTGATAGCAATTGCCTGAATAACGAACCTAACTTTTTTAAAAAACATTCATGTGAT 300 
N F D S N C L N N E P N F F K K H S C D  ( 7 2 )  
GATAATAAGGAAGCTTCATTTTTGAATCGTGCTTCTCGAAAGTTGAGGCAATTCCTTAAA 360 
D N K E A S F L N R A S R K L R Q F L K  ( 9 2 )  
ATGAATATCAGTGATGATTTCAAGCTTCACCTATCAACAGTTTCACAGGGCACATTAACA 420 
M  N T S  D D F K L H L S T V S Q G T L T  ( 1 1 2 )  
CTGCTGAACTGCACCAGCAAGGGTAAAGGAAGAAAACCACCTTCCCTGAGTGAAGCTCAA 4 80 
L  L  N  C  T  S K G K G R K P P S L S E A Q  ( 1 3 2 )  
CCCACTAAGAATTTGGAAGAGAATAAATCTTCAAAGGAACAGAAAAAACAGAATGACCTG 540 
P  T  K  N  L  E  E  N  K  S  S K E Q K K Q N D L  ( 1 5 2 )  
TGTTTCCTAAAGATACTACTACAAAAGATAAAAACTTGTTGGAATAAAATTTTGAGGGGC 600 
C F L K I L L Q K I K T C W N K I L R G  ( 1 7 2 )  
ATTAAAGAACACTGAAAATATGGAGTAGCAATATAAAACCTTGAGCTTTATTTGTGTCCT 660 
I K E H * (177) 
CCAAGAATCTATCCGCTCATGTGATTTTCAAGGGCAGAATGCCTCCTGGAAGTTACTGAA 720 
CGCATCCTGGTTAAAACAGATTACAGCAACTGAGAAATCCTTACTGTAGTACCGGAAGAT 780 
GGACCTAAACAATGGAAACCAAATCCTGCAATCAACAAAACTATTTCACATGTATGAGGA 840 
CATATATTAATTGGTATTAATTCTGAACAGTTTAAGACAATCCATGTAAGGTATTAGTTG 900 
CAATAATACTTTTTAAATGTGTTTAAAATTTTCAGAAGATATATAAAAGATATATAAATT 960 
CTGTGAAGTATATAAAGGTTATGAGGGTTAAAAATTAACATGTCATTATTACCAAAATAT 1020 
ATAGTTTTATGCCCATTATGTATACTGCCCATCAGTATACTGCAATGAGAGTGGAAATTG 1080 
TTGTCGTCTGTGCTGGAAATGTTTCAGAGTTAACAGTGAGATATGGATAAGGCCCATGAG 1140 
AATGAGTCATGTAAAGAAGCAGTAGCATAAAGGAGTCCAAGGTAACTGAAAGATATTAAG 1200 
AGATGTAGTTAAACATGAATGTATAATACAGTGCCTTTGATAAACGATATTACAGATGTT 1260 
TTAAJU^TTAAAGTAAAGAATAGTTTCACAAAACAGAAAGTCACCTGCTCTAAGGATGCTA 1320 
AACCATAGCACTGGGTTACTTTTGTCATTTATGTGTAATAAAATTTGTCTACATGAGTTT 1380 
GCAATTTGGGAAGTATATTTTTAAGAGAATAATATATGTTGGCCTTTTAATTAATGGAAT 14 40 
GTGTATATTTAATTTTGACACAATATCTGTATATAAAAATATTTTCATACAGTATTACAA 1500 
TTGCTTACTTTGGATAACATTTTTCCTTTGATAATAAATGACCTATGTATTAAAAAAAAA 1560 
AAAA 1564 
Figure 1. Nucleotide and deduced amino acid sequences of bIL-7. Nucleotide numbers are 
given to the right and the amino acid numbers are within parenthesis. The putative signal 
peptide (84-124, underlined), the three potential N-linked glycosylation sites (doubly 
underlined), and the polyadenylation signal in the 3'-untranslated region (bold) are indicated. 
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APPENDIX B 
CATIONIC LIPOSOME-MEDIATED INTRAVENOUS 
DELIVERY OF BOVINE GRANULOCYTE-COLONY 
STIMULATING FACTOR 
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Cationic liposome-mediated intravenous delivery of bovine 
granulocyte-colony stimulating factor 
Introduction 
Cationic liposomes have become one of the most commonly used vehicles for gene delivery 
both in vivo and in vitro. Although recombinant viral vectors have successfully been used for 
systemic gene delivery (Herz and Gerard, 1993, Kozarsky, et al., 1994, Yang, et al., 1994), their 
utility is often limited by deleterious side effects inherent in viral delivery systems. These side 
effects often include induction of toxic-inflammatory and immune responses and neoplastic 
transformation due to viral integration (Crystal, et al., 1994, Gao and Huang, 1995). Systemic 
delivery of cationic liposome-mediated plasmid-based genes, however, is safe, well tolerated, and 
generally has no toxicity or risk of integration associated with it (Stewart, et al., 1992, Zhu, et al., 
1993, McLean, et al., 1997). 
In an attempt to increase the number of neutrophils in the circulation and enhance their 
functional activities as an immunomodulatory measure for prevention or treatment of infectious 
diseases, bovine granulocyte-colony stimulating factor (bG-CSF) was coupled to a cationic 
liposome, DMRIE-C (1, 2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl anunonium 
bromide/cholesterol) and was delivered intravenously into jugular veins of calves. The effects 
were measured by direct peripheral blood leukocyte counts and flow cytometric analysis to 
determine neutrophil numbers per milliliter of blood sample. CD45, the common leukocyte 
antigen, was used as a surface marker for differentiation of leukocyte sub-populations. 
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Materials and Methods 
Construction of the plasmid 
The complete coding sequence of bG-CSF cDNA, previously cloned and sequenced in our 
laboratory (Heidari and Kehrli, 2000), was amplified by polymerase chain reaction. Primer 
sequences for amplification of this DNA fragment were as follows: 
5-AATATGGATCCAAACCCCCCTTGGCCCTGCC-3' (forward primer) and 
5-CAGGCAGATCTCTAGGGCrCAGCAAGGTA-3' (reverse primer). The underlined 
nucleotides are 5' extensions, which contain BamHl (GGATCC), and Bglll (AGATCT) sites 
for sub cloning of the amplified fragment into the expression vector. The expression vector 
used was VR1028 (Vical, San Diego, CA) that contains the mouse beta-glucuronidase signal 
peptide for extracellular secretion of the expressed protein. Sequence analysis of the construct 
confirmed that the cloned cDNA was in frame with the initiation codon (ATG) of the signal 
peptide. 
Plasmid preparation 
Escherichia coli strain TOPIOF' was transformed by the VR1028-bG-CSF construct and 
positive transformants were selected on Luria-Bertani plates containing 25 ng/ml Kanamycin. 
Plasmid was prepared by using the Qiagen endotoxin free plasmid isolation kit according to the 
supplier's protocol (Qiagen, Valencia, CA). 
DNA/liposome complex preparation 
A 5 ml solution of cationic liposome containing 2 mg DMRIE-C reagent (Life Technologies, 
Inc., Grand Island, NY) was added drop by drop to 5 ml of sterile saline containing 0.5 mg of 
the plasmid DNA construct. The complex was mixed gently and incubated at room temperature 
for 15-30 min. Just before administration, the solution was mixed and drawn into a disposable 
15 ml syringe fitted with an 18-guage needle, and injected into the jugular vein of each of the 
94 
three young calves (< 6 months old). For control, three other calves were injected each with 10 
ml of saline containing 2 mg liposome and 0.5 mg plasmid DNA alone (without insert) 
prepared as before. 
Total blood leukocyte counts 
Total leukocyte counts (cells/^1) were determined with whole blood collected in tubes 
containing ethyienediaminetetraacetic acid using an electronic cell counter (CellTrack, Angel 
Engineering Corp., Trumbull, CT). 
Blood leukogram determination 
For the CD45 staining process, 96-well round-bottom plates were preloaded with 10 ^1 of 
murine anti-bovine CE)45 (25 ^ g/ml; VMRD, Pullman, WA) and 10 (il of goat anti-mouse 
IgG^^ (H1 C-conjugated secondary antibody; VMRD, Pullman, WA). 50 (il of anticoagulated 
blood from each animal was added per well and mixed gently. Plates were incubated in the dark 
for 5 min at 39° C. Following incubation, erythrocytes were lysed using 150 jil/well of 
hypotonic solution (Burton, et al., 1995) for 1 min, and isotonicity was resored with 75 |il of 
hypertonic solution (Burton et al., 1995). Plates were then centrifuged (800x g for 2 min) and 
supernatant was discarded. The lysing process was repeated once more and cells were washed 
once with 200 ^1 of phosphate buffered saline solution. Cells were finally resuspended in 200 
|J of sheath fluid (Isoton 11, Coulter Diagnostics, Hialeah, FL) for flow cytometric analysis. 
A FACScan flow cytometer (Becton Dickinson, San Jose, CA) was used to acquire data from 
5,000-10,(XX) events per sample, and CellQuest software (Becton Dickinson) was used for 
fluorescence analysis. Leukocyte populations were initially gated based on their forward and 
side scatter (FSC/SSC) properties on dot plots. Erythrocytes and other cellular debris were 
gated out at this point. From this, sub populations were subsequently gated based on SSC and 
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CD45 specific fluorescence. Neutrophil percentage in the total gated leukocyte population was 
determined and used to calculate the neutrophil numbers / ml of peripheral blood sample. 
Results and Discussion 
Cationic liposome-mediated systemic gene delivery represents a promising approach for the 
analysis of gene function and regulation in vivo. Although intravenous (TV) injection of 
plasmid DNA alone has been shown to transfect many tissues analyzed, liposome-mediated 
gene delivery is much more efficient in transfection and expression level (Liu, et al., 1995, 
Ochiya, et al., 1999). It has also been shown that repeated IV injection of liposome-DNA 
complexes results in a high level of systemic transfection and expression without neutralizing 
immune responses that are generally associated with and consequently limit the repeated use of 
recombinant viral vector delivery systems (Liu et al., 1995, Ochiya et al., 1999). As mentioned, 
direct IV injection of expression plasmid DNA harboring either endogenous or exogenous 
genes has been relatively successful in the past in both transfection and expression level. A 
single rv injection of a plasmid containing human tissue kallikrein gene into spontaneously 
hypertensive rats was shown to produce a sustained reduction of blood pressure for up to 6 
weeks (Wang, et al., 1995). Expression was detected in the heart, lung, and kidney. Liposome-
mediated gene delivery, however, has been shown to increase the expression level up to a 1000 
fold in comparison to plasmid DNA alone (Templeton, et al., 1997), with tranfection being 
observed in the ovary, anterior pituitory, lymph nodes, Peyer's patches, high endothelial venules, 
and spleen, in addition to lung, heart, and kidney (McLean et al., 1997). Transfection and 
expression of liposome-mediated gene delivery has even been observed in the progeny of 
pregnant mice receiving a plasmid-based exogenous gene (Ochiya et al., 1999). 
Studies have shown that the formulation of liposomes, the size of the DNA-liposome 
complexes, the regulatory elements of the plasmid vectors (promoter/enhancer, signal peptide, 
the position of the heterologous intron, etc.) all have significant effects on the level of gene 
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expression and the number of tissues transfected (Wang et al., 1995, Templeton et al., 1997, 
Ochiya et al., 1999). 
Although IV delivery of plasmid-based genes complexed to DMRIE-C has resulted in high 
level transfection and expression (Ochiya et al., 1999), results obtained from our experiments 
were inconclusive. Figure 1 shows the results obtained from a control animal injected with 
DMRIE-C/plasmid complex (without insert). Total leukcxyte counts were determined every 
other day, three times prior to injection and up to ten times post injection. Figure 2 shows the 
results obtained from one of the calves injected with bG-CSF/ liposome complex. The data 
clearly shows a dramatic increase in the total number of white blood cells up to two weeks post 
injection in comparison to the pre-injection base line. Flow cytometric analysis revealed that 
this increase is indeed due to an increase in the number of circulating neutrophils while the 
population of other leukocyes remained unchanged (Fig. 3). Data obtained from two other 
calves receiving the same complex revealed no change in the total number of leukocytes or 
neutrophils. Whether the increase in the number of neutrophils observed in a single calf was 
due to a prior infection, or the formulation and the batch of liposome used for that calf was 
different, is not clear. Further experiments using different mammalian expression vectors, 
different liposome formulations, and possibly different routes of delivery are needed to 
determine if such studies have any clinical value for prevention or treatment of infectious 
diseases. 
It is of interest to mention that intramuscular injection of interleukin-5 (eosinophil 
differentiation factor) into mice was shown to increase the number of circulating eosinophils by 
more than 26% for up to two weeks post injection (Tokui, et al., 1997). Intramuscular injection 
or gene gun-mediated delivery would be two alternative methods to study the effect of DNA 
delivery of bG-CSG in vivo. 
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Figure 1. Time course of peripheral blood leukocyte counts before and after DNA injection. 
Liposome/plasmid DNA complex (without insert) was injected FV into the jugular vein of a 
calf on day zero and total WBC counts were determined three times prior to injection (base 
line counts) and up to 9 times post injection. 
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Figure 2. Time course of peripheral blood leukocyte counts before and after DNA injection. 
Liposome/bG-CSF DNA complex was injected IV on day zero and peripheral leukocyte 
counts were determined before and after injection. 
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Figure 3. Time course of peripheral blood neutrophil counts before and after DNA injection. 
Flow cytometric analysis was performed on the blood samples of the calf in Figure 2 to 
determine the number of neutrophils/ml during the course of the experiment. 
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